Modified hematopoietic stem cells and uses thereof

By modifying hematopoietic stem cells in the contractile region to make them more resistant to mobilization factors, apoptosis factors, and homing factors, the problems of low efficiency and high toxicity of existing treatment methods are solved, and safer and more efficient HSC treatment is achieved.

CN118922533APending Publication Date: 2024-11-08CANADIAN STEM CELL TECH CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380020569.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-06
Filing Date
2023-01-04
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing treatments for hemoglobinopathies, such as hydroxyurea, L-glutamine, and vorcelothorax, have limited efficacy, and hematopoietic stem cell transplantation requires toxic myeloablative therapy, posing serious short-term and long-term clinical risks.

Method used

By passing a suspension of hematopoietic stem cells through the contractile portion, the effective load is used to modify HSCs to enhance their resistance to mobilization factors, apoptosis factors, exhaustion factors, and homing factors, thereby improving the mobilization, survival, and homing capabilities of HSCs and avoiding myeloablative therapy.

Benefits of technology

It significantly improves the resistance of HSCs to mobilization factors, enhances the homing ability of HSCs, improves the implantation efficiency and survival rate of HSCs in the bone marrow of subjects, and reduces the need for toxic myeloablative therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004980957890000311
    Figure BDA0004980957890000311
  • Figure BDA0004980957890000321
    Figure BDA0004980957890000321
  • Figure BDA0004980957890000322
    Figure BDA0004980957890000322
Patent Text Reader

Abstract

The present disclosure provides a method for producing a modified HSC wherein the method comprises passing a cell suspension comprising the cells and a payload through a constriction wherein the constriction deforms the cells, thereby causing perturbation of the cells such that the payload enters the cells. In some aspects, the payload is capable of enhancing one or more characteristics of the HSC such that the HSC is better implanted within the bone marrow of a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This PCT application claims the benefit of priority to U.S. Provisional Application Nos. 63 / 296,544, filed on January 5, 2022, and 63 / 374,622, filed on September 6, 2022, each of which is incorporated herein by reference in its entirety.

[0003] References to sequence listings submitted electronically

[0004] The contents of the electronically submitted Sequence Listing in the form of an .XML file (Name: 4821_007PC02_Seqlisting_ST26; Size: 20,966 bytes; and Creation Date: January 3, 2023) submitted with this application are incorporated herein by reference in its entirety. Field of the Invention

[0005] The present disclosure generally relates to methods of generating hematopoietic stem cells (HSCs) with enhanced properties, such as increased resistance to mobilization and / or apoptotic factors. Background of the Invention

[0007] Hemoglobinopathies are a group of inherited monogenic blood cell disorders (e.g., sickle cell disease and thalassemia syndromes) characterized by abnormal production or structure of hemoglobin molecules. Modell et al., Bull World Health Organ 86:480-487 (2008); and Kohne et al., Dtsch Arztebl Int 108:532 (2011). Such disorders may be associated with severe pain and multi-organ ischemic damage, increased risk of infection, and even premature death. Current treatment options include small molecule-based therapies such as hydroxyurea, L-glutamine, and voxelotor, all of which show limited efficacy and are non-curative. And, although hematopoietic stem cell transplantation (HSCT) has had some success, such treatment regimens require the use of toxic myeloablative therapy to deplete the endogenous stem cell compartment, thereby making room for the implantation of therapeutically modified HSCs in the bone marrow niche. Busulfan is a commonly used myeloablative agent that is associated with severe short-term and long-term clinical adverse events (e.g., cerebellar hemorrhage, myelodysplastic syndrome, veno-occlusive disease). Morales-Ramirez et al., Arch Med Res 37:316-321 (2006); Iwamoto et al., Cancer Sci 95:454-458 (2004); and Finazii et al., Br J Haematol 110:577-583 (2000). Therefore, there remains a need for a more efficient and safer approach to HSC-based treatment regimens for the treatment of hemoglobinopathies and other similar conditions. Summary of the invention

[0008] Disclosed herein is a method for producing modified hematopoietic stem cells (HSCs), the method comprising passing a cell suspension comprising a population of HSCs through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSCs, and wherein the payload is capable of modifying the HSCs such that the HSCs exhibit: (i) increased resistance to mobilization factors, (ii) increased resistance to apoptotic factors, (iii) increased resistance to depletion factors, (iv) increased expression of homing factors, or (v) a combination thereof.

[0009] In some aspects, after modification, the HSC has an increased resistance to mobilization factors of at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold, compared to a corresponding HSC that did not pass through the constriction under one or more parameters. In some aspects, after modification, the HSC has an increased resistance to apoptotic factors of at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold, compared to a corresponding HSC that did not pass through the constriction under one or more parameters. In some aspects, after modification, the resistance of the HSC to depletion factors is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through a constriction under one or more parameters. In some aspects, the expression of homing factors on the HSC is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through a constriction under one or more parameters.

[0010] Also provided herein is a method of increasing homing of hematopoietic stem cells (HSCs) to the bone marrow of a subject in need thereof, the method comprising passing a cell suspension comprising the HSCs through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSCs, and wherein the payload is capable of modifying the HSCs such that the HSCs exhibit increased homing to the bone marrow when administered to the subject.

[0011] In some aspects, after modification, the HSC exhibits increased expression of homing receptors. In some aspects, the expression of homing receptors on HSCs is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under one or more parameters.

[0012] The present disclosure also provides a method for increasing the survival of hematopoietic stem cells in a subject in need thereof, the method comprising passing a cell suspension comprising HSCs through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSCs, and wherein the payload is capable of modifying the HSCs such that the HSCs exhibit increased survival when administered to the subject.

[0013] In some aspects, after modification, the HSC exhibits increased resistance to apoptotic factors. In some aspects, the HSC has an increased resistance to apoptotic factors by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times, or at least about 50 times, compared to a corresponding HSC that has not passed through a constriction under one or more parameters.

[0014] Provided herein is a method for causing hematopoietic stem cells (HSCs) to engraft into the bone marrow of a subject in need thereof, the method comprising passing a cell suspension comprising the HSCs through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSCs, and wherein the payload is capable of modifying the HSCs such that the HSCs engraft into the bone marrow of the subject when administered to the subject.

[0015] In some aspects, after modification, the HSC exhibits: (i) increased resistance to mobilization factors, (ii) increased resistance to apoptotic factors, (iii) increased resistance to depletion factors, (iv) increased expression of homing factors, or (v) a combination thereof.

[0016] In some aspects, the resistance of the HSC to mobilization factors is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under one or more parameters. In some aspects, the resistance of the HSC to apoptotic factors is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under one or more parameters. In some aspects, the resistance of the HSC to depletion factors is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under one or more parameters. In some aspects, the expression of homing factors on the HSC is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under one or more parameters.

[0017] Also provided herein is a method for producing a modified hematopoietic stem cell (HSC), the method comprising delivering a payload intracellularly to the HSC, wherein the payload is capable of modifying the HSC so that the HSC exhibits: (i) increased resistance to mobilization factors, (ii) increased resistance to apoptotic factors, (iii) increased resistance to exhaustion factors, (iv) increased expression of homing factors, or (v) a combination thereof. Also provided herein is a method for increasing the homing of hematopoietic stem cells (HSC) to the bone marrow of a subject in need thereof, the method comprising delivering a payload intracellularly to the HSC, wherein the payload is capable of modifying the HSC so that the HSC exhibits increased homing to the bone marrow when administered to the subject. Also provided herein is a method for increasing the survival of hematopoietic stem cells (HSC) in a subject in need thereof, the method comprising delivering a payload intracellularly to the HSC, wherein the payload is capable of modifying the HSC so that the HSC exhibits increased survival when administered to the subject. Also provided herein is a method for causing hematopoietic stem cells (HSC) to be implanted in the bone marrow of a subject in need thereof, the method comprising delivering a payload intracellularly to the HSC, wherein the payload is capable of modifying the HSC so that the HSC is implanted in the subject's bone marrow when administered to the subject. In some aspects, the payload is transiently expressed in the modified HSC.

[0018] In some aspects, the payload comprises a homing receptor, a cytokine, a growth factor, a cell adhesion molecule, a proliferation agent, a survival factor, a combination thereof, or a modulator thereof.

[0019] In some aspects, the homing receptor comprises CXCR4, CXCR2, or both. In some aspects, CXCR4 comprises an amino acid sequence different from the corresponding wild-type amino acid sequence shown in SEQ ID NO: 1. In some aspects, the amino acid sequence of CXCR4 comprises one of the following mutations: R334X, A175F, H113A, D171N, D262N, I284A, H281A, Q200W, Q200A, or a combination thereof.

[0020] In some aspects, cytokines include stem cell factor (SCF), Fms related tyrosine kinase 3 ligand (Flt3L) or both. In some aspects, growth factors include thrombopoietin (TPO). In some aspects, cell adhesion molecules include integrins, selectins or both. In some aspects, cell adhesion molecules include VLA-4, VLA-5, LFA-1 or their combination. In some aspects, proliferators include activators of signal pathways involved in cell proliferation. In some aspects, signal pathways include PI3K-ATK, Ras-ERK or both. In some aspects, survival factors include Bcl-2, Bcl-xL, MCL-1, Ced-9, bfl-1 or their combination.

[0021] In some aspects, Bcl-2 comprises an amino acid sequence that differs from the corresponding wild-type amino acid sequence set forth in SEQ ID NO: 9. In some aspects, the amino acid sequence of Bcl-2 comprises a G101V mutation, a D103Y mutation, or both.

[0022] In some aspects, regulating and controlling agent can increase the expression and / or activity of homing receptor, cytokine, growth factor, cell adhesion molecule, proliferator, survival factor or their combination.In some aspects, regulating and controlling agent comprises prostaglandin (such as prostaglandin E2 (PGE2)).In some aspects, regulating and controlling agent can reduce or prevent (such as knocking down) the activity of the inhibitor of homing receptor, cytokine, growth factor, cell adhesion molecule, proliferator, survival factor or their combination.

[0023] In some aspects, the inhibitor comprises GPRASP1 / 2, CD26, or both.

[0024] In some aspects, the mobilization factor comprises Plerixaflor, AMD3465, GROβ, G-CSF, anti-CD117 antibody or a combination thereof. In some aspects, the apoptosis factor comprises a Bcl-2 inhibitor (e.g., Venetoclax), an MCL-1 inhibitor (e.g., S63845 or S64315), a BCL-XL inhibitor or a combination thereof.

[0025] In some aspects, the payload comprises a nucleic acid. In some aspects, the nucleic acid comprises DNA, RNA, or both. In some aspects, the RNA comprises mRNA, siRNA, miRNA, lncRNA, tRNA, shRNA, self-amplifying mRNA (saRNA), PNA, locked nucleic acid (LNA), or a combination thereof.

[0026] In some aspects, the above methods include contacting the HSC with the payload at the following time: (i) before the cell suspension passes through the constriction, (ii) during the cell suspension passes through the constriction, (iii) after the cell suspension passes through the constriction, or (iv) a combination thereof. In some aspects, the HSC is contacted with the payload before the cell suspension passes through the constriction. In some aspects, the HSC is contacted with the payload during the cell suspension passes through the constriction. In some aspects, the HSC is contacted with the payload after the cell suspension passes through the constriction.

[0027] In some aspects, the HSCs are CD34+, CD90+, CD45RA-, and negative for lineage markers (e.g., CD2, CD3, CDl lb, CDl lc, CD14, CD16, CD19, CD24, CD56, CD66b, and CD235).

[0028] In some aspects, the constriction is within the microfluidic chip.

[0029] In some aspects, one or more parameters are selected from cell density; pressure; length, width and / or depth of the constriction; diameter of the constriction; diameter of the cells; temperature; inlet angle of the constriction; outlet angle of the constriction; length, width and / or width of the approach zone; surface properties of the constriction (e.g., roughness, chemical modification, hydrophilicity, hydrophobicity); operating flow rate; payload concentration; viscosity, osmotic pressure, salt concentration, serum content and / or pH of the cell suspension; time in the constriction; shear rate in the constriction; type of payload, or a combination thereof.

[0030] In some aspects, the cell density is at least about 1 x 10 5 cells / mL, at least about 2x10 5 cells / mL, at least about 3x10 5 cells / mL, at least about 4x10 5 cells / mL, at least about 5x10 5 cells / mL, at least about 6x10 5 cells / mL, at least about 7x10 5 cells / mL, at least about 8x10 5 cells / mL, at least about 9x10 5 cells / mL, at least about 1x10 6 cells / mL, at least about 2x10 6 cells / mL, at least about 3x10 6 cells / mL, at least about 4x10 6 cells / mL, at least about 5x10 6cells / mL, at least about 6x10 6 cells / mL, at least about 7x10 6 cells / mL, at least about 8x10 6 cells / mL, at least about 9x10 6 cells / mL, at least about 1x10 7 cells / mL, at least about 2x10 7 cells / mL, at least about 3x10 7 cells / mL, at least about 4x10 7 cells / mL, at least about 5x10 7 cells / mL, at least about 6x10 7 cells / mL, at least about 7x10 7 cells / mL, at least about 8x10 7 cells / mL, at least about 9x10 7 cells / mL, at least about 1x10 8 cells / mL, at least about 1.1x10 8 cells / mL, at least about 1.2x10 8 cells / mL, at least about 1.3x10 8 cells / mL, at least about 1.4x10 8 cells / mL, at least about 1.5x10 8 cells / mL, at least about 2.0x10 8 cells / mL, at least about 3.0x10 8 cells / mL, at least about 4.0x10 8 cells / mL, at least about 5.0x10 8 cells / mL, at least about 6.0x10 8 cells / mL, at least about 7.0x10 8 cells / mL, at least about 8.0x10 8 cells / mL, at least about 9.0x10 8 cells / mL or at least about 1.0x10 9 cells / mL or more.

[0031] In some aspects, the pressure is at least about 20 psi, at least about 25 psi, at least about 30 psi, at least about 35 psi, at least about 40 psi, at least about 45 psi, at least about 50 psi, at least about 55 psi, at least about 60 psi, at least about 65 psi, at least about 70 psi, at least about 75 psi, at least about 80 psi, at least about 85 psi, at least about 90 psi, at least about 95 psi, at least about 100 psi, at least about 110 psi, at least about 120 psi, at least about 130 psi, at least about 140 psi, or at least about 150 psi.

[0032] In some aspects, the diameter of the constriction is about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 99% of the diameter of the HSC.

[0033] In some aspects, the length of the constriction is at most about 100 μm. In some aspects, the length of the constriction is less than about 0.1 μm, less than about 0.2 μm, less than about 0.3 μm, less than about 0.4 μm, less than about 0.5 μm, less than about 0.6 μm, less than about 0.7 μm, less than about 0.8 μm, less than about 0.9 μm, less than about 1 μm, less than about 2.5 μm, less than about 5 μm, less than about 7.5 μm, less than about 10 μm, less than about 12.5 μm, less than about 15 μm, less than about 20 μm, less than about 30 μm, less than about 40 μm, less than about 50 μm, less than about 60 μm, less than about 70 μm, less than about 80 μm, less than about 90 μm, or less than about 100 μm. In some aspects, the length of the constriction is about 0.1 μm, about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1 μm, about 2.5 μm, about 5 μm, about 7.5 μm, about 10 μm, about 12.5 μm, about 15 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm or about 100 μm.

[0034] In some aspects, the width of the constriction is at most about 10 μm. In some aspects, the width of the constriction is less than about 1 μm, less than about 2 μm, less than about 3 μm, less than about 4 μm, less than about 5 μm, less than about 6 μm, less than about 7 μm, less than about 8 μm, less than about 9 μm, or less than about 10 μm. In some aspects, the width of the constriction is between about 1 μm and about 10 μm. In some aspects, the width of the constriction is about 1 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, or about 10 μm.

[0035] In some aspects, the depth of the constriction is at least about 1 μm. In some aspects, the depth of the constriction is at least about 2 μm, at least about 3 μm, at least about 4 μm, at least about 5 μm, at least about 10 μm, at least about 20 μm, at least about 30 μm, at least about 40 μm, at least about 50 μm, at least about 60 μm, at least about 70 μm, at least about 80 μm, at least about 90 μm, at least about 100 μm, at least about 110 μm, or at least about 120 μm. In some aspects, the depth of the constriction is about 5 μm to about 90 μm. In some aspects, the depth is about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, or about 90 μm.

[0036] In some aspects, the constriction comprises a width and a depth, wherein the width of the constriction is about 1 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, or about 10 μm, and wherein the depth of the constriction is about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, or about 90 μm.

[0037] In some aspects, the HSC is contacted with the multiple payloads at the following times: (i) before the cell suspension passes through the constriction, (ii) during the passage of the cell suspension through the constriction, (iii) after the cell suspension passes through the constriction, or (iv) a combination thereof, such that passing the cell suspension through the constriction under one or more parameters allows at least two or more of the multiple payloads to enter the HSC.

[0038] In some aspects, the plurality of payloads comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 or more payloads. In some aspects, at least two or more of the plurality of payloads enter the cell in parallel. In some aspects, at least two or more of the plurality of payloads enter the cell sequentially.

[0039] In some aspects, the method provided herein includes passing the cell suspension through a plurality of constrictions. In some aspects, a plurality of constrictions comprise at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 550, at least about 600, at least about 650, at least about 700, at least about 750, at least about 800, at least about 850, at least about 900, at least about 950, at least about 1,000 or more individual constrictions.

[0040] In some aspects, each of the plurality of constrictions is identical. In some aspects, one or more of the plurality of constrictions is different.

[0041] In some aspects, one or more of the constrictions differ in length, depth, width, or a combination thereof. In some aspects, each of the plurality of constrictions is associated with the same payload. In some aspects, one or more of the plurality of constrictions is associated with different payloads.

[0042] In some aspects, multiple constrictions are contained within a single microfluidic chip. In some aspects, multiple constrictions are contained within multiple microfluidic chips, wherein each of the multiple microfluidic chips comprises a constriction. In some aspects, each of the multiple microfluidic chips is identical. In some aspects, one or more of the multiple microfluidic chips are different.

[0043] In some aspects, the time interval between passing the cell suspension through a first constriction and a second constriction of the plurality of constrictions is less than about 1 μs, less than about 1 second, less than about 1 minute, less than about 30 minutes, less than about 1 hour, less than about 6 hours, less than about 12 hours, less than about 1 day, less than about 2 days, less than about 3 days, less than about 4 days, or less than about 5 days.

[0044] In some aspects, the plurality of constrictions include a first constriction associated with a first payload and a second constriction associated with a payload, wherein a cell suspension is passed through the first constriction to allow the first payload to enter the HSC, and then the cell suspension is passed through the second constriction to allow the second payload to enter the HSC.

[0045] Provided herein is a hematopoietic stem cell (HSC) population produced using any of the methods disclosed herein. Also provided herein is a composition comprising an HSC population produced herein and a pharmaceutically acceptable carrier. Also provided herein is a kit comprising an HSC population produced herein and instructions for use.

[0046] Provided herein is a composition comprising a population of modified hematopoietic stem cells (HSCs), wherein the modified HSCs comprise a payload that is capable of: (i) increasing the resistance of the modified HSCs to mobilization factors, (ii) increasing the resistance of the modified HSCs to inhibitors of anti-apoptotic factors, (iii) increasing the resistance of the modified HSCs to depletion factors, (iv) increasing the expression of homing factors on the modified HSCs, or (v) a combination thereof.

[0047] In some aspects, the modified HSC has an increased resistance to mobilization factors by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that has not been modified to include a payload. In some aspects, the modified HSC has an increased resistance to inhibitors of anti-apoptotic factors by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that has not been modified to include a payload. In some aspects, the modified HSC has an increased resistance to depletion factors by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that has not been modified to contain a payload. In some aspects, the expression of a homing receptor on a modified HSC is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that has not been modified to contain a payload.

[0048] In some aspects, the payload is transiently expressed in the modified HSC. In some aspects, the payload includes homing receptors, cytokines, growth factors, cell adhesion molecules, proliferators, survival factors, combinations thereof, or regulators thereof. In some aspects, the homing receptor includes CXCR4, CXCR2, or both. In some aspects, CXCR4 includes an amino acid sequence different from the corresponding wild-type amino acid sequence shown in SEQID NO:1. In some aspects, the amino acid sequence of CXCR4 includes one of the following mutations: R334X, A175F, H113A, D171N, D262N, I284A, H281A, Q200W, Q200A, or combinations thereof. In some aspects, cytokines include stem cell factor (SCF), Fms-related tyrosine kinase 3 ligands (Flt3L), or both. In some aspects, growth factors include thrombopoietin (TPO). In some aspects, cell adhesion molecules include integrins, selectins, or both. In some aspects, cell adhesion molecules include VLA-4, VLA-5, LFA-1 or their combination. In some aspects, proliferators include the activator of the signal pathway involved in cell proliferation. In some aspects, signal pathway includes PI3K-ATK, Ras-ERK or both. In some aspects, survival factors include Bcl-2, Bcl-xL, MCL-1, Ced-9, bfl-1 or their combination. In some aspects, Bcl-2 includes an amino acid sequence different from the corresponding wild-type amino acid sequence shown in SEQ ID NO:9. In some aspects, the amino acid sequence of Bcl-2 includes G101V mutation, D103Y mutation or both. In some aspects, regulating and controlling agents can increase the expression and / or activity of homing receptors, cytokines, growth factors, cell adhesion molecules, proliferators, survival factors or their combination. In some aspects, regulating and controlling agents include prostaglandins (e.g., prostaglandin E2 (PGE2)). In some aspects, the modulator can reduce or prevent (e.g., knock down) the activity of the inhibitor of homing receptor, cytokine, growth factor, cell adhesion molecule, proliferator, survival factor or their combination. In some aspects, the inhibitor includes GPRASP1 / 2, CD26 or both. In some aspects, the mobilization factor includes plerixafor, AMD3465, GRO β, G-CSF, anti-CD117 antibody or their combination. In some aspects, the apoptosis factor includes Bcl-2 inhibitor (e.g., venetola), MCL-1 inhibitor (e.g., S63845 or S64315), BCL-XL inhibitor or their combination. In some aspects, the payload includes nucleic acid. In some aspects, nucleic acid includes DNA, RNA or both.In some aspects, the RNA comprises mRNA, siRNA, miRNA, lncRNA, tRNA, shRNA, self-amplifying mRNA (saRNA), PNA, locked nucleic acid (LNA), or a combination thereof.

[0049] Disclosed herein is a method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject any of the HSC populations generated herein or any of the compositions described herein.

[0050] In some aspects, the disease or disorder comprises a blood disorder. In some aspects, the blood disorder comprises sickle cell disease (SCD), thalassemia syndrome, severe aplastic anemia, Fanconi anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, congenital amegakaryocytic thrombocytopenia, or a combination thereof.

[0051] In some aspects, the disease or disorder comprises an immune disorder. In some aspects, the immune disorder comprises severe combined immunodeficiency, Wiskott-Aldrich syndrome, or both.

[0052] In some aspects, the disease or disorder comprises a metabolic disorder. In some aspects, the metabolic disorder comprises Krabbe disease (GLD), Hurler syndrome, adrenoleukodystrophy, metachromatic leukodystrophy, Fabry disease, Gaucher disease, cystinosis, Hunter syndrome, Pompe disease, or a combination thereof.

[0053] In some aspects, the subject has not received a myeloablative conditioning regimen prior to administration of the HSC population or composition. In some aspects, the myeloablative conditioning regimen comprises irradiation, chemotherapy, small molecules, antibodies, or a combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 Shown is the engraftment of extruded human CD34+ HSCs in the bone marrow of NSG (top) and NBSGW (bottom) mice (untreated) six weeks after adoptive transfer. HSC engraftment is shown as a percentage of total CD45+ bone marrow cells as measured using flow cytometry. "hCD45" = human CD45 (i.e., adoptively transferred human HSCs); and "mCD45" = mouse CD45 (i.e., endogenous mouse HSCs).

[0055] Figure 2A, Figure 2B as well as Figure 2C Shown are the presence of β-catenin in peripheral blood ( Figure 2A ),spleen( Figure 2B ) and bone marrow ( Figure 2C ) within the adoptively transferred human HSC. The frequency of cells is shown as a percentage of total CD45+ cells. "NBSGW NC" = HSCs extruded without any payload and administered to NBSGW mice; "NBSGW SQZ" = HSCs extruded with GFP mRNA and administered to NBSGW mice; "NSGNC" = HSCs extruded without any payload and administered to NSG mice; and "NSG SQZ" = HSCs extruded with GFP mRNA and administered to NSG mice, i.e., Groups A, B, C, and D in Table 5, respectively (see Example 1).

[0056] Figure 3A and Figure 3B The expression kinetics of different CXCR4 variants in human CD34+ HSCs processed using CXCR4 variant mRNA extrusion are shown. The expression of CXCR4 as measured using flow cytometry at 4 hours, 24 hours, 48 ​​hours and 72 hours after extrusion is shown. Figure 3A In the figure, CXCR4 expression is shown as geometric mean fluorescence intensity. Figure 3B In the Figure 6, the expression of CXCR4 variants is shown as the fold increase compared to the corresponding expression in control HSCs (i.e., no payload and no extrusion processing). The different groups shown are as follows: (1) no payload and no extrusion processing "NC"; (2) extrusion processing without any payload ("empty"); (3) extrusion processing with wild-type CXCR4 mRNA ("CXCR4wt"); (4) extrusion processing with CXCR4-A175F variant mRNA ("CXCR4 A175F"); (5) extrusion processing with CXCR4-A175F+R334X variant mRNA ("CXCR4 A175FR334X"); and (6) extrusion processing with CXCR4-R334X variant mRNA ("CXCR4R334X"), i.e., Groups AF in Table 6 (see Example 2), respectively.

[0057] Figure 3CA comparison of the inhibition of CXCL12 signaling by plerixafor in human CD34+ HSCs extruded with wild-type CXCR4 mRNA (middle bar) or with CXCR4 variant (comprising the A175F modification) mRNA (right bar) is provided. HSCs that were not extruded (i.e., treated with plerixafor alone) were used as controls (left bar).

[0058] Figure 3D and Figure 3E Shown is CXCR4 expression in extruded human CD34+ HSCs following adoptive transfer into NSG mice. Figure 3D A schematic diagram of the experimental design is provided. As indicated, human CD34+ HSCs were processed for extrusion without payload (ie, empty extrusion; "ES") or with mRNA encoding CXCR4 (ie, a bone marrow homing receptor) prior to transfer. Figure 3E Comparison of CXCR4 expression (geometric mean fluorescence intensity) of adoptively transferred cells within the bone marrow 24 hours after adoptive transfer is presented.

[0059] Figure 4A and Figure 4B The expression kinetics of Bcl-2 variants in human CD34+ HSCs processed using Bcl-2 variant mRNA extrusion are shown. Bcl-2 expression as measured using flow cytometry is shown 4 hours, 24 hours, 48 ​​hours, and 72 hours after extrusion. Figure 4A In the figure, Bcl-2 expression is shown as geometric mean fluorescence intensity. Figure 4B In the Figures, Bcl-2 expression is shown as a fold increase compared to the corresponding expression in control HSCs (i.e., no payload and no extrusion). The different groups shown are as follows: (1) no payload and no extrusion "NC"; (2) extrusion without any payload ("empty"); (3) extrusion with wild-type Bcl-2 mRNA ("Bcl-2wt"); and (4) extrusion with Bcl-2-G101V variant mRNA ("Bcl-2 G101V"), i.e., groups A, B, G, and H in Table 6, respectively (see Example 2).

[0060] Figure 5A and Figure 5B Shown is Bcl-2 expression in extruded human CD34+ HSCs following adoptive transfer into NSG mice. Figure 5A A schematic diagram of the experimental design is provided. As shown, human CD34+ HSCs were extruded with control mRNA or Bcl-2 variant mRNA (ie, containing the G101V amino acid modification) prior to transfer. Figure 5BComparison of Bcl-2 expression (geometric mean fluorescence intensity) of adoptively transferred cells in the bone marrow 24 hours after adoptive transfer is presented.

[0061] Fig. 6A and Figure 6B Shown is competitive engraftment of human CD34+ HSCs processed using GFP mRNA ("GFP HSCs") or Bcl-2 variant mRNA (ie, containing the G101V amino acid modification) ("Bcl-2 variant HSCs") extruded after adoptive transfer into NSG mice. Fig. 6A A schematic diagram of the experimental design is provided. As shown, mice were administered GFP HSCs and Bcl-2 variant HSCs at a 1:1 ratio, and some mice were further administered Bcl-2 and MCL-1 inhibitors (ie, venetoclax and S63845, respectively). Figure 6B A comparison of the frequency of transferred HSCs (as a percentage of human cells) within the bone marrow of the animals 24 hours after adoptive transfer is presented. DETAILED DESCRIPTION

[0062] The present disclosure is generally about the method for producing hematopoietic stem cells (HSC) showing one or more enhanced characteristics. Specifically, the method provided herein includes passing a cell suspension comprising an HSC colony through a contraction under one or more parameters. In some aspects, this causes a transient disturbance in the cell membrane of the HSC, through which a payload can enter the HSC and thereby enhance one or more characteristics of the HSC (e.g., increase resistance to mobilization factors, increase resistance to apoptotic factors, increase resistance to exhaustion factors, increase expression of homing receptors, or a combination thereof). Non-limiting examples of various aspects are shown in the present disclosure.

[0063] I. General Technology

[0064] Some techniques and procedures described or referred to herein are generally well understood by those skilled in the art and are commonly used using conventional methods, such as the widely used methods described in the following: Molecular Cloning: A Laboratory Manual (Sambrook et al., 4th edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2012); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 2003); the series Methods in Enzymology (Academic Press, Inc.); PCR 2: A Practical Approach (MJ MacPherson, BD Hames and GR Taylor, eds., 1995); Antibodies, A Laboratory Manual (Harlow and Lane, eds., 1988); Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications (RI Freshney, 6th edition, J. Wiley and Sons, 2010); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (edited by JECellis, Academic Press, 1998); Introduction to Cell and Tissue Culture (JPMather and PERoberts, Plenum Press, 1998); Cell and Tissue Culture: Laboratory Procedures (edited by A.Doyle, JBGriffiths and DG Newell, J.Wiley and Sons, 1993-8); Handbook ofExperimental Immunology (DMWeir and CC Blackwell, eds., 1996); Gene Transfer Vectors for Mammalian Cells (JMMiller and MPCalos (ed., 1987); PCR: The Polymerase ChainReaction, (Mullis et al., ed., 1994); Current Protocols in Immunology (JEColigan et al., 1991); Short Protocols in Molecular Biology (Ausubel et al., ed., J.Wiley and Sons, 2002); Immunobiology (CA Janeway et al., 2004); Antibodies (P. Finch, 1997); Antibodies: APractical Approach (edited by D. Catty., IRL Press, 1988-1989); Monoclonal Antibodies: APractical Approach (edited by P. Shepherd and C. Dean, Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and JD Capra, Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (VT DeVita et al., JS Lippincott Company, 2011).

[0065] II. Definitions

[0066] For the purpose of interpreting this specification, the following definitions will apply and where appropriate, terms used in the singular will also include the plural and vice versa. In the event of any conflict between any definition set forth below and any document incorporated herein by reference, the definition set forth herein will prevail. Other definitions are set forth in the detailed description.

[0067] Unless otherwise indicated, as used herein, the singular terms "a", "an", and "the" entity refer to one or more (or one or more) of the entity. Thus, the terms "a" (or "an" or "the"), "one or more", and "at least one" are used interchangeably herein.

[0068] It should be understood that aspects and aspects of the present disclosure described herein include "comprising" aspects and aspects, "consisting of," and "consisting essentially of." It should also be understood that wherever the language "comprising" is used herein to describe aspects and aspects, otherwise similar aspects or aspects described with the terms "consisting of" and / or "consisting essentially of" are also provided.

[0069] In addition, "and / or" when used in this article should be regarded as specifically disclosing each of the two specified features or components in the presence or absence of the other. Therefore, the term "and / or" when used in phrases such as "A and / or B" in this article is intended to include "A and B", "A or B", "A" (alone) and "B" (alone). Similarly, the term "and / or" when used in phrases such as "A, B and / or C" is intended to cover each of the following aspects: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0070] For all compositions described herein and all methods using the compositions described herein, the compositions may include or may "consist essentially of the listed components or steps". When a composition is described as "consisting essentially of the listed components", the composition contains the listed components and may also contain other components that do not substantially affect the disclosed method, but does not contain any other components that substantially affect the disclosed method except those components explicitly listed; or if the composition does not contain additional components except those components listed that substantially affect the disclosed method, then the composition does not contain sufficient concentrations or amounts of additional components to substantially affect the disclosed method. When a method is described as "consisting essentially of the listed steps", the method contains the listed steps and may also contain other steps that do not substantially affect the disclosed method, but does not contain any other steps that substantially affect the disclosed method except those steps explicitly listed. As a non-limiting specific example, when a composition is described as "consisting essentially of one component", the composition may additionally contain any amount of a pharmaceutically acceptable carrier, vehicle or diluent and other such components that do not substantially affect the disclosed method.

[0071] Units, prefixes, and symbols are expressed in a form accepted by the International System of Units (SI). Numerical ranges include numbers that define the ranges. The headings provided herein are not limitations on the various aspects of the disclosure and may be provided with such headings by reference to the specification as a whole. Therefore, the terms defined immediately below are more fully defined by reference to the specification as a whole.

[0072] The term "about" is used herein to mean approximately, roughly, roughly, or in the vicinity. When the term "about" is used in conjunction with a numerical range, it modifies the range by expanding the boundaries above and below the stated numerical values. In general, the term "about" can modify a numerical value to be above and below the stated value, with a change of up or down (higher or lower), for example, 10%.

[0073] As used herein, the term "apoptosis" refers to killing cells by activating programmed cell death pathways. Cells undergoing apoptosis can generally be characterized by morphological and biochemical changes, such as DNA fragmentation, chromatin condensation, chromosome migration, nuclear edge collection, apoptotic body formation, mitochondrial swelling, mitochondrial cristae widening, mitochondrial permeability transition pore opening, mitochondrial proton gradient dissipation, caspase activity or a combination thereof. The term "apoptotic factor" refers to any agent capable of inducing apoptosis in cells (e.g., HSC). In some aspects, the apoptotic factor can act directly on cells to induce apoptosis. In some aspects, the apoptotic factor works indirectly by inhibiting the activity of anti-apoptotic factors. As used herein, the term "anti-apoptotic factor" refers to any molecule capable of reducing or preventing apoptosis. Non-limiting examples of anti-apoptotic factors include Bcl-2, MCL-1, BCL-XL and a combination thereof. Non-limiting examples of apoptotic factors include inhibitors of Bcl-2 ("Bcl-2 inhibitors") (e.g., venetoclax), inhibitors of MCL-1 ("MCL-1 inhibitors") (e.g., S63845 and S64315), inhibitors of BCL-XL ("BCL-XL inhibitors"), or combinations thereof. Such inhibitors are also referred to herein as "inhibitors of anti-apoptotic factors".

[0074] The term "constriction" as used herein refers to a narrowed channel. In some aspects, the constriction is a microfluidic channel such as contained in a microfluidic device. In some aspects, the constriction is a pore or is contained in a pore. In the case where the constriction is a pore, in some aspects, the pore is contained on the surface. Unless otherwise indicated, the term constriction refers to both microfluidic channels and pores, as well as other suitable constrictions available in the art. Therefore, where appropriate, the disclosures related to microfluidic channels may also be applicable to pores and / or other suitable constrictions available in the art. Similarly, where appropriate, the disclosures related to pores may also be applicable to microfluidic channels and / or other suitable constrictions available in the art.

[0075] As used herein, the terms "deformation" and "distortion" (including their derivatives) refer to physical changes in cells. As described herein, when a cell passes through a constriction (such as those disclosed herein), it experiences various forces due to the constraining physical environment, including but not limited to mechanical deformation forces and / or shear forces, thereby causing disturbances in the cell membrane. As used herein, a "disturbance" in a cell membrane refers to any opening in the cell membrane that does not exist under normal steady-state conditions (e.g., no deformation forces are applied to the cell). The disturbance may include a hole, tear, cavity, hole, pore, fracture, gap, perforation, or a combination thereof.

[0076] As used herein, the term "depletion factor" refers to any agent that can induce depletion (i.e., removal or deletion) of HSC from a subject's stem cell niche (e.g., bone marrow). As is apparent from the present disclosure, in some aspects, HSC can be depleted from a stem cell niche by mobilizing HSC (e.g., from bone marrow to peripheral blood). Non-limiting examples of depletion factors include CD117 antibody-drug conjugates. In some aspects, HSC can be depleted by inducing cell death (e.g., by inducing HSC apoptosis). Therefore, in some aspects, the term "depletion factor" can be used interchangeably with the term "mobilization factor" and / or "apoptosis factor". The present disclosure provides non-limiting examples of other mobilization factors and apoptosis factors elsewhere.

[0077] As used herein, the term "filter" refers to a porous article that allows selective passage through the pores. In some aspects, the term refers to a surface or film containing pores.

[0078] As used herein, the term "hematopoietic stem cell" or "HSC" refers to a subset of pluripotent stem cells that produce all blood or immune cell types, including myeloid (e.g., monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes / platelets, dendritic cells, mast cells) and lymphoid lineages (e.g., innate lymphoid cells, T cells, B cells, NKT cells, NK cells), and have multi-lineage hematopoietic differentiation potential and maintain self-renewal activity. The method for identifying HSC that can be used in the present disclosure is known in the art. For example, in some aspects, HSC that can be used in the present disclosure can be identified based on their phenotypic expression (e.g., using flow cytometry) as CD34+, CD90+, CD45RA-, and lack the expression of any lineage markers (CD2, CD3, CD11b, CD11c, CD14, CD16, CD19, CD24, CD56, CD66b, and CD235).

[0079] As used herein, the term "heterogeneous" refers to something that has a structure or composition that is mixed or non-uniform. For example, when used to describe pores present in a constriction provided herein, such terms may refer to pores having different sizes, shapes, or distributions within a given surface.

[0080] As used herein, the term "homing factor" refers to any agent that can induce cells to home (i.e., migrate) to a specific compartment in a subject. For example, in some aspects, the homing factor provided herein can induce HSC to migrate to the bone marrow when administered to a subject. Non-limiting examples of homing factors include homing receptors. "Homing receptor" refers to a molecule that is expressed on the surface of a cell (e.g., HSC) and exhibits affinity for a ligand so that cells expressing the homing receptor preferentially migrate toward the ligand. As further described elsewhere in the present disclosure, in some aspects, a homing receptor is a chemokine receptor, such as CXCR4 and CXCR2.

[0081] As used herein, the term "homogeneous" refers to something that is consistent or uniform in structure or composition. For example, when used to describe the pores present in the constrictions provided herein, such terms may refer to the pores having a consistent size, shape, or distribution within a given surface.

[0082] As used herein, the term "membrane" refers to a selective barrier or sheet containing pores. The term includes, but is not limited to, a flexible sheet-like structure that acts as a border or lining. In some aspects, the term refers to a surface or filter containing pores. This term is different from the term "cell membrane", which refers to a semipermeable membrane surrounding the cytoplasm of a cell.

[0083] As used herein, the term "mobilization" (or its grammatical derivatives) refers to the recruitment of HSCs from a first location (e.g., a stem cell niche, such as the bone marrow) to a second location (e.g., a tissue, peripheral blood, or an organ). In some aspects, the first location is the bone marrow and the second location is the peripheral blood. As used herein, the term "mobilization factor" includes any agent capable of inducing HSC mobilization (e.g., from the bone marrow to the peripheral blood). Non-limiting examples of mobilization factors include: plerixafor (e.g., ), AMD3465 (CXCR4 antagonist), Groβ (CXCR2 agonist, induces MMP-9 secretion), granulocyte colony stimulating factor (G-CSF), anti-CD117 (c-kit) antibody, chemotherapy (e.g. cyclophosphamide, etoposide (e.g. and ), POL6326 (CXCR4 antagonist), TG-0054 (CXCR4 antagonist), BKT140 (anti-SDF-1), bortezomib (proteasome inhibitor, downregulates VLA4 / VCAM-1 axis) (e.g. ), PTH (PTH receptor agonist, expands BM HSC), CDX-301 (FLT3 agonist), LY2510924 (CXCR4 antagonist), natalizumab (VLA-4 antagonist) (e.g. ), meloxicam (nonsteroidal anti-inflammatory drug) (e.g. ), eltrombopag (TPO receptor agonist) (e.g. ), ALX-0651 (anti-CXCR4 nanobody) and combinations thereof. See, for example, Domingues et al., Int J Hematol 105:141-152 (2017); Bakanay et al., Bone Marrow Transplantation 47:1154-1163 (2012), both of which are incorporated herein by reference in their entirety. Or combinations thereof.

[0084] As used herein, the term "polynucleotide" or "nucleic acid" refers to a polymeric form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length. Therefore, this term includes, but is not limited to, single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derived nucleotide bases. The backbone of a polynucleotide may include sugar and phosphate groups (such as can be found in RNA or DNA generally) or modified or substituted sugar or phosphate groups. Alternatively, the backbone of a polynucleotide may include polymers of synthetic subunits such as aminophosphoric acid esters and may therefore be oligodeoxynucleoside phosphoramidates (P-NH2) or mixed aminophosphoric acid ester-phosphodiester oligomers. In addition, double-stranded polynucleotides may be obtained from chemically synthesized single-stranded polynucleotide products by synthesizing complementary chains and annealing the chains under appropriate conditions or by using DNA polymerase to synthesize complementary chains de novo with appropriate primers.

[0085] The terms "polypeptide" and "protein" are used interchangeably to refer to polymers of amino acid residues, and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers and polymers of amino acid residues. The definition encompasses both full-length proteins and fragments thereof. The term also includes post-expression modifications of the polypeptide, such as glycosylation, sialylation, acetylation, phosphorylation, etc. In addition, for the purposes of this disclosure, "polypeptide" refers to proteins including modifications to the native sequence, such as deletions, additions and substitutions (generally conservative in nature), as long as the protein maintains the desired activity. These modifications may be intentional, such as by site-directed mutagenesis, or may be accidental, such as by mutations of the host producing the protein or errors due to PCR amplification.

[0086] As used herein, the term "pore" refers to an opening in a material, including but not limited to a hole, tear, cavity, pore, break, gap, or perforation. In some aspects, the term refers to a pore in the surface of a microfluidic device (such as those described in the present disclosure) (where necessary). In some aspects, a pore may refer to a pore in a cell wall and / or cell membrane (where necessary).

[0087] As used herein, the term "reference" HSC refers to an HSC that has not been modified using the extrusion processing methods provided herein. For example, in some aspects, a reference HSC refers to a corresponding HSC that has been exposed to a payload but using an alternative delivery method known in the art (e.g., electroporation or liposome transfection). In some aspects, a reference HSC refers to a corresponding HSC that has undergone extrusion processing but without any of the payloads described herein. In some aspects, a reference HSC refers to a corresponding HSC that has not been modified (i.e., not extruded and not delivered any payload).

[0088] As used herein, the term "survival factor" refers to any agent that can promote the survival of cells (e.g., HSCs). Such agents are also referred to herein as "anti-apoptotic factors". For example, in some aspects, survival factors can reduce or prevent cells from undergoing apoptosis. Non-limiting examples of survival factors include Bcl-2, Bcl-xL, MCL-1, Ced-9, bfl-1, or a combination thereof. As is apparent from the present disclosure, the modification of HSCs to show increased expression of survival factors by the extrusion processing methods provided herein can increase the survival of HSCs compared to reference HSCs.

[0089] III. Methods of the Disclosure

[0090] In some aspects, the present disclosure relates to methods for producing HSCs with enhanced properties by delivering a payload into HSCs, wherein the payload can enhance one or more properties of the HSCs. As further described herein, such methods include passing a cell suspension comprising a HSC population through a contraction under one or more parameters. When the cells pass through the contraction, they are transiently deformed so that the cell membrane of the HSC is disturbed. The disturbance in the cell membrane allows the payload to enter or be loaded into the cell (e.g., by diffusion). The specific process of passing cells through the contraction and causing transient deformation is referred to herein as "extrusion processing" or "extrusion".

[0091] As further described herein, the extrusion processing method disclosed herein has certain unique characteristics that other delivery methods known in the art do not have. For example, in addition to the improved ability to deliver various types of payloads to cells, the extrusion processing method described herein exerts minimal sustained effects on cells. Compared with traditional delivery methods such as electroporation, the extrusion processing method disclosed herein retains the structural and functional integrity of the extruded cells. In contrast to the delivery method provided herein, electroporation can induce extensive and sustained changes in gene expression, which can cause non-specific cell (e.g., human T cell) activation and delayed proliferation after antigen stimulation. Using the inventive method, any changes to cells (e.g., disturbances in the cell membrane) are instantaneous and are quickly repaired after the cells are removed from the constriction.

[0092] As demonstrated herein, using such improved delivery methods, different aspects of HSCs can be modified so that the HSCs described herein are structurally and functionally different from corresponding cells naturally occurring in nature. For example, in some aspects, by using payloads (e.g., CXCR4 and / or Bcl-2) that play an important role in HSC implantation within the subject's bone marrow (e.g., promoting homing to the bone marrow and / or increasing survival), such payloads can be expressed (e.g., overexpressed) in HSCs using the extrusion processing methods provided herein, and thereby allowing HSCs to better implant when administered to a subject.

[0093] In addition, in some aspects, by using a payload that can increase resistance to mobilization factors, the extrusion processing methods provided herein can enhance the ability of HSC to resist the effects of mobilization factors. Similarly, in some aspects, by using a payload that can increase the resistance of HSC to apoptotic factors, the extrusion processing methods disclosed herein can enhance the ability of HSC to resist the effects of apoptotic factors. And, by using a payload that can increase the resistance of HSC to depletion factors, the extrusion processing methods provided herein can be used to produce HSC with increased resistance to such depletion factors. As further described elsewhere in the present disclosure, such enhanced properties can be particularly useful because they can be implanted in the bone marrow of a subject without the need for harsh and toxic myeloablative pretreatment.

[0094] While the present disclosure generally discloses the use of payloads that are capable of increasing the specific properties described above (i.e., resistance of HSCs to mobilization factors, resistance of HSCs to apoptotic factors, resistance of HSCs to depletion factors, and / or increased expression of homing factors), it will be apparent to one skilled in the art that the disclosure relating to such payloads may equally apply to other types of payloads, such as those that enhance one or more other properties of HSCs.

[0095] In some aspects, provided herein is a method of producing a modified HSC, wherein the method comprises passing a cell suspension through a constriction under one or more parameters, wherein the cell suspension comprises a population of HSCs, wherein passing the cell suspension through the constriction under one or more parameters allows a payload to enter the HSCs (e.g., by a transient perturbation formed in the cell membrane of the HSCs as the cell suspension passes through the constriction), and wherein the payload is capable of modifying the HSCs such that the HSCs exhibit: (i) increased resistance to mobilization factors, (ii) increased resistance to apoptotic factors, (iii) increased resistance to depletion factors, (iv) increased expression of homing factors, or (v) any combination thereof. Non-limiting examples of such payloads are provided elsewhere in the present disclosure.

[0096] In some aspects, the modified HSC produced using the methods provided herein is at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold greater than a reference HSC. In some aspects, the HSC produced using the methods provided herein is at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold greater than a reference HSC. In some aspects, compared with a reference HSC, the HSC produced using the method provided herein has a greater resistance to depletion factors than at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times. In some aspects, compared with a reference HSC, the HSC produced using the method provided herein has an increased expression of homing factors. In some aspects, the expression of homing factors increases by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times.

[0097] Thus, in some aspects, the methods provided herein can be used to increase the homing of HSCs when administered to a subject in need thereof (e.g., due to increased resistance to mobilization factors, increased resistance to depletion factors, and / or increased expression of homing factors). In some aspects, such methods include passing a cell suspension comprising HSCs through a constriction under one or more parameters such that a payload enters the HSCs (e.g., by a transient perturbation formed in the cell membrane of the HSCs as the cell suspension passes through the constriction), wherein the payload is capable of modifying the HSCs such that the HSCs exhibit increased homing to the bone marrow when administered to a subject.

[0098] In some aspects, the methods provided herein can also be used to increase the survival of HSC when administered to a subject in need thereof (e.g., due to increased resistance to apoptotic factors). In some aspects, such methods include passing a cell suspension comprising HSC through a constriction under one or more parameters such that a payload enters the HSC (e.g., by a transient perturbation formed in the cell membrane of the HSC as the cell suspension passes through the constriction), wherein the payload is capable of modifying the HSC such that the HSC exhibits increased survival when administered to a subject.

[0099] As will be apparent to those skilled in the art and as further described elsewhere in the present disclosure (see, e.g., the section entitled "Therapeutic Uses"), the above methods have various important clinical implications. For example, in some aspects, by enhancing one or more characteristics of the HSC described herein, the engraftment of the HSC when administered to a subject can be improved. Thus, in some aspects, the present disclosure relates to a method for promoting engraftment of HSCs into the bone marrow of a subject in need thereof, the method comprising passing a cell suspension comprising the HSCs through a constriction under one or more parameters such that a payload enters the HSCs (e.g., by a transient perturbation formed in the cell membrane of the HSCs as the cell suspension passes through the constriction), wherein the payload is capable of modifying the HSCs such that the HSCs are engrafted into the subject's bone marrow when administered to the subject.

[0100] Compared with reference to HSC, the method provided herein can increase the implantation of the HSC administered. In some aspects, compared with the implantation observed after the administration of reference to HSC, the implantation of the HSC administered increases by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times.

[0101] In some aspects, the above method also includes contacting HSC with a payload (such as described herein) before passing a cell suspension comprising HSC through a contraction. As is apparent from the present disclosure, in some aspects, contacting HSC with a payload before extrusion can help improve delivery efficiency, because once a disturbance is formed in the cell membrane by extrusion processing, the payload will be able to enter the cell. In some aspects, before passing a cell suspension through a contraction, the method provided herein includes contacting HSC with a payload to produce a cell suspension. In some aspects, the method provided herein includes contacting HSC with a payload when the cell suspension passes through a contraction. In some aspects, contacting HSC with a payload first during the cell suspension passes through a contraction. In some aspects, contacting HSC with a payload before and during the step of passing through a contraction. In some aspects, the method provided herein includes contacting HSC with a payload after the cell suspension passes through a contraction. In some aspects, contacting cells with a payload first after the cell suspension passes through a contraction. In some aspects, the HSC is contacted with a payload before, during, and / or after the passing step. As further described elsewhere in the present disclosure, when the HSC is contacted with a payload after the passing step, the contact occurs shortly after the HSC passes through the constriction, such that there is still a perturbation in the cell membrane.

[0102] As used herein, "contact" that can occur between a HSC and a payload (e.g., as described herein) includes that the cell can be in contact with the payload as long as the payload is able to enter the cell upon the presence of a perturbation within the cell membrane of the cell. To help illustrate, in some aspects, a cell and a payload are in contact with each other if both are present in the same cell suspension.

[0103] III.A. Cell suspension

[0104] In some aspects, the cell suspension described herein includes any suitable HSC known in the art that can be modified (e.g., by introducing a payload) using the extrusion processing method described herein. Although the present application generally describes the use of HSC, it will be apparent to those skilled in the art that the disclosure provided herein may be applicable to other types of stem cells that can be used to treat diseases or disorders (e.g., blood disorders) described herein. As used herein, the term "stem cell" refers to cells that not only have the ability to self-replicate but also have the ability to differentiate into other types of cells. In some aspects, stem cells that can be used for the present disclosure include induced pluripotent stem cells (iPSC), embryonic stem cells (ESC), tissue-specific stem cells (e.g., liver stem cells, cardiac stem cells, or neural stem cells), mesenchymal stem cells, hematopoietic stem cells (HSC), or combinations thereof. In some aspects, stem cells are HSC.

[0105] As demonstrated herein, the delivery of a payload to a cell can be regulated by one or more parameters of the process by which a cell suspension passes through a constriction. In some aspects, specific characteristics of a cell suspension can affect the delivery of a payload to a cell. Such characteristics include, but are not limited to, osmotic pressure, salt concentration, serum content, cell concentration, pH, temperature, or a combination thereof. The disclosure provides other parameters relevant to the disclosure elsewhere.

[0106] In some aspects, the cell suspension comprises a homogenous cell population (e.g., a purified HSC population). In some aspects, the cell suspension comprises a heterogeneous cell population (e.g., a mixture of whole blood or cells comprising HSC, such as in a saline solution or in a physiological medium other than blood). In the case where the cell suspension comprises a heterogeneous cell population, in some aspects, HSC may account for about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 60%, about 70%, about 80% or about 90% of the total cell population. In some aspects, the heterogeneous cell population has undergone an enrichment step so that HSC accounts for a greater percentage of the total cell population.

[0107] In some respects, the cell suspension comprises an aqueous solution. In some respects, the aqueous solution comprises cell culture medium, PBS, salt, sugar, somatomedin, animal-derived product, expansion material, surfactant, lubricant, vitamin, polypeptide, agent affecting actin polymerization or a combination thereof. In some respects, the cell culture medium comprises DMEM, OptiMEM, EVIDM, RPMI, XVivo10 or a combination thereof. In addition, the solution buffer may include one or more lubricants (pluronic or other surfactants) that can be designed to reduce or eliminate the blocking effect on the surface and improve cell viability. Exemplary surfactants include but are not limited to poloxamer, polysorbate, sugar (such as mannitol), animal-derived serum and albumin.

[0108] When the suspension includes certain types of cells, in some aspects, the cells can be treated with a solution that helps deliver the payload to the interior of the cell. In some aspects, the solution includes an agent that affects actin polymerization. In some aspects, the agent that affects actin polymerization includes Latrunculin A, cytochalasin, colchicine, or a combination thereof. For example, in some aspects, the cells can be incubated in a depolymerization solution (such as Latrunculin A) for about 1 hour before passing the cells through the contraction to depolymerize the actin cytoskeleton. In some aspects, the cells can be incubated in colchicine (Sigma) for about 2 hours before passing the cells through the contraction to depolymerize the microtubule network.

[0109] In some aspects, a cell suspension characteristic that can affect the delivery of a payload to cells is the viscosity of the cell suspension. As used herein, the term "viscosity" refers to the internal resistance to flow exhibited by a fluid. In some aspects, the viscosity of the cell suspension is between about 8.9 x 10 -4 Pa·s is about 4.0x10 -3 Pa·s, about 8.9x10 -4 Pa·s is about 3.0x10 - 3 Pa·s, about 8.9x10 -4 Pa·s is about 2.0x10 -3 Pa·s or about 8.9x10 -4 Pa·s is about 1.0x10 -3Pa·s. In some aspects, the viscosity is between about 0.89cP to about 4.0cP, about 0.89cP to about 3.0cP, about 0.89cP to about 2.0cP, or about 0.89cP to about 1.0cP. In some aspects, the shear thinning effect is observed, wherein the viscosity of the cell suspension is reduced under the condition of shear strain. The viscosity can be measured by any suitable method known in the art, including but not limited to a viscometer (such as a glass capillary viscometer) or a rheometer. The viscometer measures the viscosity under a flow condition, and the rheometer is used to measure the viscosity that changes with the flow condition. In some aspects, the viscosity is measured for a shear thinning solution (such as blood). In some aspects, the viscosity is measured between about 0°C and about 45°C. For example, the viscosity of the cell suspension can be measured at room temperature (e.g., about 20°C), physiological temperature (e.g., about 37°C), above physiological temperature (e.g., greater than about 37°C to about 45°C or higher), low temperature (e.g., about 0°C to about 4°C), or at a temperature between these exemplary temperatures.

[0110] III.B. Payload

[0111] As described herein, in some aspects, the cell suspension further comprises one or more payloads, such as one or more characteristics of HSC that can be improved so that HSC can be better implanted when applied to a subject (e.g., increasing HSC resistance to mobilization factors, increasing HSC resistance to apoptotic factors, increasing HSC resistance to exhaustion factors, increasing homing factor expression in HSC, or a combination thereof). Non-limiting examples of payloads that can be used for the present disclosure include homing factors (e.g., homing receptors), cytokines, growth factors, cell adhesion molecules, proliferators, survival factors, or a combination thereof. In some aspects, payloads that can be used for the present disclosure include regulators of such payloads. The term "regulator" when used to describe payloads that can be used for the present disclosure refers to any agent that can regulate (e.g., increase and / or decrease) the expression and / or activity of other payloads described herein. For example, in some aspects, payloads that can be used for the present disclosure include regulators of homing factors. In some aspects, payloads that can be used for the present disclosure include regulators of cytokines. In some aspects, payloads include regulators of growth factors. In some aspects, the payload comprises a regulator of a cell adhesion molecule. In some aspects, the payload comprises a regulator of a proliferation agent. In some aspects, the payload comprises a regulator of a survival factor. Other aspects of such payloads are further described below.

[0112] As is apparent from the present disclosure, in some aspects, the payload that can be used for the present disclosure is transiently expressed in the modified HSC, so that any modification of one or more characteristics of the HSC mediated by the payload is not permanent (i.e., transient expression). For example, in some aspects, the payload is expressed in the HSC for less than about one day, less than about two days, less than about three days, less than about four days, less than about five days, less than about six days, less than about seven days, less than about eight days, less than about nine days, or less than about 10 days. In some aspects, the payload is expressed in the HSC for about one day, about two days, about three days, about four days, about five days, about six days, about seven days, about eight days, about nine days, or about 10 days.

[0113] As described and confirmed herein, in some aspects, the payload that can be used to produce the modified HSC described herein comprises a homing factor. For example, in some aspects, the payload comprises a homing receptor, such as a homing receptor that participates in the homing and repopulation of HSC in the bone marrow. Non-limiting examples of homing receptors that can be used for the present disclosure include CXCR4, CXCR2, or both. In some aspects, the homing receptor is CXCR4. CXCR4 interacts with CXCL12, which is mainly secreted by mesenchymal stromal cells present in the bone marrow niche. This interaction has been described as being important in the homing and retention of HSC in the bone marrow niche. See, for example, Karpova et al., Stem Cell 33:2391-2399 (2015); and Sugiyama et al., Immunity 25:977-988 (2006).

[0114] Therefore, in some aspects, compared with reference to HSC, using the extrusion processing method provided herein, the expression of CXCR4 on HSC can be increased. In some aspects, compared with the corresponding expression on reference to HSC, the expression of CXCR4 on HSC increases by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times. In some aspects, the expression of CXCR4 on HSC increases and can help increase the homing and / or retention of HSC in the bone marrow niche.

[0115] In some aspects, CXCR4 can be modified to help further improve one or more characteristics of HSC produced using the methods provided herein. For example, as will be apparent to those skilled in the art, in order to promote the implantation of any adoptively transferred HSC (e.g., as part of HSC transplantation therapy), the endogenous stem cell compartment must be depleted / reduced to make room for the adoptively transferred HSC. Plerixafor is an FDA-approved small molecule (i.e., a mobilization factor) that inhibits the interaction between CXCR4 and CXCL12, and thereby promotes HSC mobilization from the bone marrow to the peripheral blood. Therefore, in some aspects, the payload that can be used for the present disclosure includes a CXCR4 variant, the CXCR4 variant including one or more mutations that can confer resistance to plerixafor or any other similar mobilization factor. Compared to the corresponding wild-type amino acid sequence shown in SEQ ID NO:1, a non-limiting example of such a CXCR4 variant includes a mutation A175F (see Tables 1 and 2).

[0116] Table 1. CXCR4 variant amino acid sequences

[0117]

[0118]

[0119] Table 2. CXCR4 variant nucleotide sequences

[0120]

[0121]

[0122]

[0123]

[0124] It will be apparent to those skilled in the art that by modifying HSCs to express such CXCR4 variants, in some aspects, plerixafor can be used to selectively mobilize unmodified HSCs (e.g., endogenous HSCs) from the bone marrow and thus allow for improved engraftment of adoptively transferred modified HSCs.

[0125] In some aspects, the CXCR4 variant may include one or more mutations that enhance the function of CXCR4 (e.g., enhance the interaction between CXCR4 and CXCL12). Non-limiting examples of such CXCR4 variants include mutation R334X (see Table 1) compared to the corresponding wild-type amino acid sequence shown in SEQ ID NO: 1. In some aspects, the CXCR4 variant includes A175F and R334X mutations compared to the corresponding wild-type amino acid sequence shown in SEQ ID NO: 1. Non-limiting examples of other mutations of the CXCR4 variants described herein include H113A, D171N, D262N, I284A, H281A, Q200W, Q200A, or combinations thereof.

[0126] In some aspects, the homing receptor is CXCR2 or a variant thereof. In some aspects, using the extrusion processing method provided herein, the expression of CXCR2 on HSC can be increased. In some aspects, compared with reference HSC, the expression of CXCR2 can be increased by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times.

[0127] In some aspects, useful payloads for the present disclosure include survival factors, such as those that increase the survival of HSCs when expressed (or overexpressed) in HSCs. Non-limiting examples of survival factors include Bcl-2, Bcl-xL, MCL-1, Ced-9, bfl-1, or a combination thereof.

[0128] In some aspects, the effective load comprises Bcl-2. Qing et al., Blood 123: 1002 (2014). Therefore, in some aspects, compared with reference to HSC, using the extrusion processing method provided herein, the expression of Bcl-2 on HSC can be increased. In some aspects, compared with the corresponding expression on reference to HSC, the expression of Bcl-2 on HSC increases by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times.

[0129] In some aspects, Bcl-2 can be modified to help further improve one or more characteristics of HSC produced using the methods provided herein. Venetola is a BH3 mimetic approved by the FDA that specifically targets and inhibits Bcl-2. Therefore, in some aspects, the payload that can be used for the present disclosure includes a Bcl-2 variant that includes one or more mutations that can confer resistance to Venetola or any other similar apoptotic factor. Compared to the corresponding wild-type amino acid sequence shown in SEQ ID NO:9, non-limiting examples of such Bcl-2 variants include mutations G101V, D103Y or both (see Tables 3 and 4). It will be apparent to those skilled in the art that by modifying HSC to express such Bcl-2 variants, in some aspects, Venetola can be used to selectively deplete unmodified HSC (e.g., endogenous HSC) from the bone marrow, and thus allow the implantation of the modified HSC of adoptive transfer to be improved.

[0130] Table 3. Bcl-2 variant amino acid sequences

[0131]

[0132] Table 4. Bcl-2 variant nucleotide sequences

[0133]

[0134]

[0135] In some aspects, the payload comprises MCL1 apoptosis regulator (MCL-1). MCL-1 has been shown to be important for the survival of HSC and other hematopoietic progenitor cells. Bohler et al., Haematologica 106:3136-3148 (2021); and Chin et al., Front Cell Dev 9:704547 (2021). Therefore, in some aspects, compared with reference HSC, using the extrusion processing method provided herein, the expression of MCL-1 on HSC can be increased. In some aspects, compared with the corresponding expression on reference HSC, the expression of MCL-1 on HSC increases by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times.

[0136] In some aspects, the payload comprises Bcl-xL. In some aspects, the expression of Bcl-xL on HSC can be increased using the extrusion processing methods provided herein compared to a reference HSC. In some aspects, the expression of Bcl-xL on HSC increases by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times, or at least about 50 times compared to the corresponding expression on a reference HSC.

[0137] In some aspects, the payload comprises Ced-9. In some aspects, the expression of Ced-9 on HSCs can be increased using the extrusion processing methods provided herein compared to a reference HSC. In some aspects, the expression of Ced-9 on HSCs is increased by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times, or at least about 50 times compared to the corresponding expression on a reference HSC.

[0138] In some aspects, the payload comprises bfl-1. In some aspects, the expression of bfl-1 on HSCs can be increased using the extrusion processing methods provided herein compared to a reference HSC. In some aspects, the expression of bfl-1 on HSCs is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to the corresponding expression on a reference HSC.

[0139] In some aspects, the effective load that can be used for the present disclosure comprises cytokines or growth factors, such as those that play a role in the implantation of HSC in the subject's bone marrow. In some aspects, such effective load comprises stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), thrombopoietin (TPO), or a combination thereof.

[0140] In some aspects, using the extrusion processing methods provided herein, HSC can be modified to express greater levels of cytokines or growth factors described herein, wherein greater expression allows HSC to be better implanted in the bone marrow of a subject. In some aspects, compared with a reference HSC, the expression of SCF in HSC can be increased by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times. In some aspects, compared with a reference HSC, the expression of Flt3L can be increased by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times. In some aspects, the expression of TPO in HSCs can be at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold as compared to a reference HSC.

[0141] In some aspects, the payload that can be used for the present disclosure comprises cell adhesion molecules, such as those involved in HSC transportation to the subject's bone marrow.For example, in some aspects, the cell adhesion molecules comprise integrin, selectin or both.The non-limiting examples of suitable integrin and selectin are known in the art and include, for example, VLA-4, VLA-5, LFA-1 and their combinations.In some aspects, compared with reference to HSC, using the extrusion processing method provided herein, the expression of cell adhesion molecules on HSC can increase.In some aspects, compared with reference to HSC, the expression of cell adhesion molecules can increase at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times.

[0142] In some aspects, the effective load that can be used for the present disclosure includes a proliferator. As used herein, the term "proliferator" refers to any molecule that can induce cell (e.g., HSC) proliferation. In some aspects, the proliferator induces the activation of the signaling pathway (e.g., PI3K-ATK, Ras-ERK, or both) involved in regulating cell proliferation. Therefore, in some aspects, compared with reference to HSC, using the extrusion processing method provided herein, the expression and / or activity of the proliferator in HSC can be increased. In some aspects, the increased proliferator expression and / or activity are related to the increased HSC proliferation. In some aspects, compared with reference to HSC, the proliferation of the HSC produced using the present disclosure increases by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times, or at least about 50 times.

[0143] As described herein, in some aspects, the payloads useful in the present disclosure include agents (i.e., modulators) that can regulate the expression and / or activity of other payloads described herein. For example, G protein-coupled receptor-associated sorting proteins 1 and 2 (GPRASP1 / 2) signaling has been described as inhibiting CXCR4 expression. It has been shown that knockdown of GPRASP1 / 2 increases CXCR4 expression in HSC. Morales-Hernandez et al., Blood 135:1111-1123 (2020); and Hernandez et al., Exp Hematol 64:S88 (2018). Therefore, in some aspects, the payloads useful in the present disclosure can reduce and / or inhibit the expression and / or activity of GPRASP1 / 2, so that CXCR4 expression in HSC increases. For example, in some aspects, the payload may include siRNA (or any other gene editing tool) that selectively targets GPRASP1 / 2. Similarly, CD26 has also been shown to hinder the expression and / or activity of CXCR4, and thereby induce the mobilization of HSC. Fang et al., Stem Cell Res Ther 12(1):17(2021). Therefore, in some aspects, the payload that can be used in the present disclosure can reduce and / or inhibit the expression and / or activity of CD26 (e.g., siRNA targeting CD26), so that the expression of CXCR4 is increased.

[0144] In addition to the above, payloads that can reduce or prevent the expression and / or activity of endogenous genes involved in HSC engraftment can also be used in the present disclosure. For example, such payloads can be used to reduce the expression of homing receptors (e.g., CXCR4) naturally expressed on endogenous HSCs, such that endogenous HSCs are mobilized and thus allow for the engraftment of greater therapeutic HSCs that have been modified to express higher levels of homing receptors.

[0145] Any of the payloads described herein may be present in a cell suspension before, during, and / or after a step in which the cell suspension passes through a constriction. In some aspects, the cell suspension comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 or more payloads. As further described elsewhere in the disclosure, in some aspects, a cell suspension may be passed through a plurality of constrictions. In such aspects, when a cell passes through one or more of a plurality of constrictions, a payload may be loaded into the cell. In some aspects, each time a cell passes through one or more of a plurality of constrictions, a payload is loaded into the cell. When multiple payloads are involved, each of the payloads may be identical. In some aspects, one or more of the payloads are different.

[0146] Therefore, as is apparent from the present disclosure, in some aspects, multiple payloads can be delivered to cells using the extrusion processing methods described herein. In some aspects, multiple payloads can be delivered to cells using a single extrusion process (e.g., a cell suspension comprises multiple payloads, and the multiple payloads are delivered to cells in combination; "parallel delivery"). In some aspects, multiple payloads can be delivered to cells sequentially. As used herein, the term "sequential delivery" refers to multiple payloads being delivered to cells, wherein the first payload is delivered to cells, and then the second (or subsequent) payload is delivered to cells. In some aspects, extrusion processing can be used to deliver the first payload, the second payload, or the first and second payloads to cells. For example, in some aspects, extrusion processing can be used to deliver the first payload to cells, and non-extrusion processing can be used to deliver the second payload to cells (e.g., transfection). In some aspects, non-extrusion processing can be used to deliver the first payload to cells (e.g., transfection), and extrusion processing can be used to deliver the second payload to cells. In some aspects, a first extrusion may be used to deliver a first payload to a cell, and then a second extrusion may be used to deliver a second payload to a cell (also referred to herein as "sequential extrusion" or "sequential extrusion processing"). Thus, sequential delivery that may be used in the present disclosure may include multiple extrusion processes. In some aspects, each of the multiple extrusion processes delivers a separate payload to a cell. In some aspects, one or more of the multiple extrusion processes do not involve delivering a payload. For example, in some aspects, the sequential delivery method described herein includes a first extrusion, a second extrusion, and a third extrusion, wherein the first extrusion includes passing cells without any payload through a first constriction, the second extrusion includes passing cells from the first extrusion through a second constriction to deliver the first payload to the cell, and the third extrusion includes passing cells from the second extrusion through a third constriction to deliver the second payload to the cell. Without being limited by any theory, in some aspects, passing cells through a first constriction (i.e., a first extrusion) without any payload can help prepare the cells for subsequent payload delivery, for example, improving the delivery efficiency of the first payload and / or the second payload.

[0147] In some aspects, multiple payloads can be delivered to cells repeatedly (e.g., at least twice, at least three times, at least four times, at least five times, or more) using the extrusion processing methods described herein. As further described elsewhere in this disclosure (see, e.g., the section entitled "Constriction"), in some aspects, each of the multiple extrusion processing methods can be the same (e.g., the same parameters). In some aspects, one or more of the multiple extrusion processing methods can be different (e.g., one or more of the delivery parameters described herein are different).

[0148] As is apparent from the present disclosure, the payload that can be used for the present disclosure is not particularly limited, as long as the payload can modify HSC so that HSC exhibits one or more improved characteristics after modification. Non-limiting examples of suitable payloads include nucleic acids, polypeptides, lipids, carbohydrates, small molecules, metal-containing compounds, antibodies, transcription factors, nanoparticles, liposomes, fluorescently labeled molecules, or combinations thereof. In some aspects, nucleic acids include DNA, RNA, or both. In some aspects, DNA includes recombinant DNA, cDNA, genomic DNA, or a combination thereof. In some aspects, RNA includes siRNA, mRNA, miRNA, lncRNA, tRNA, shRNA, self-amplification mRNA (saRNA), PNA, LNA, or a combination thereof. In some aspects, RNA is mRNA.

[0149] As further described and confirmed herein, the extrusion processing methods provided herein can be used to deliver payloads to HSCs alone or in combination (e.g., at least two, at least three, at least four, at least five, at least six, at least seven, at least about eight, at least about nine, or all of the exemplary transcription factors listed). In some aspects, in the case of a combination of payloads, a single extrusion process can be used to deliver them to HSCs (e.g., parallel delivery). In some aspects, the combination of payloads can be delivered to HSCs repeatedly. For example, in some aspects, a first extrusion process is used to deliver a combination of payloads to HSCs; then, a second extrusion process is used to deliver the combination of payloads to cells again. In some aspects, the first extrusion process includes a microfluidic device (e.g., a chip) having multiple rows of constrictions, so that the extrusion process is performed on a single microfluidic device (e.g., a chip). As further described herein, in some aspects, the second extrusion process can be performed immediately after the cell passes through the first extrusion process (e.g., immediately after the cell passes through the constriction of the first extrusion process). In some aspects, the second extrusion process can be performed some time after the first extrusion process (e.g., at least about 1 minute, at least about 30 minutes, at least about 1 hour, at least about 6 hours, at least about 12 hours, or at least about 1 day after the cells pass through the constriction of the first extrusion process).

[0150] While the present disclosure primarily refers to the use of constrictions to deliver the payloads described herein to HSCs, it will be apparent to one skilled in the art that in some aspects, the payloads may be delivered to HSCs using any suitable delivery method known in the art.

[0151] III.C. Contraction

[0152] III.C.1. Microfluidic channels

[0153] As described herein, a constriction is used to induce physical distortion in a cell, such that a perturbation is formed within the cell membrane of the cell, thereby allowing the payload to be delivered into the cell. In some aspects, the constriction is within a channel (referred to herein as a "microfluidic channel" or "channel") contained within a microfluidic device. Where multiple channels are involved, in some aspects, the multiple channels may be placed in parallel and / or in series within a microfluidic device. In some aspects, the cells described herein can pass through at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 550, at least about 600, at least about 650, at least about 700, at least about 750, at least about 800, at least about 850, at least about 900, at least about 950, at least about 1,000, or more separate constrictions. In some aspects, a cell described herein passes through greater than about 1,000 individual constrictions.

[0154] In some aspects, multiple constrictions may be part of a single microfluidic device (e.g., a multi-row constriction chip). In some aspects, one or more of the multiple constrictions may be part of different microfluidic devices. For example, in some aspects, the cells (e.g., HSCs) described herein undergo a first extrusion process, in which the cells pass through a first constriction in a first microfluidic device (e.g., a chip). Then, after the cells undergo the first extrusion process (e.g., through the first constriction), the cells undergo a second extrusion process, in which the cells pass through a second constriction in a second microfluidic device (e.g., a chip). In some aspects, each of the constrictions is the same (e.g., having the same length, width, and / or depth). In some aspects, one or more of the constrictions are different. Where multiple constrictions are used, the multiple constrictions may include a first constriction associated with a first payload (e.g., mRNA encoding CXCR4 or a variant thereof), and a second constriction associated with a second payload (e.g., mRNA encoding Bcl-2 or a variant thereof), wherein the cell suspension passes through the first constriction such that the first payload is delivered to one or more cells in the plurality of cells, and then the cell suspension passes through the second constriction such that the second payload is delivered to one or more cells in the plurality of cells. In some aspects, the cell suspension passes through the second constriction at least about 1 minute, at least about 30 minutes, at least about 1 hour, at least about 6 hours, at least about 12 hours, or at least about 1 day after the cell suspension passes through the first constriction.

[0155] In some aspects, in the case where a cell suspension passes through multiple constrictions (e.g., multiple extrusion processes), the cells remain viable after passing through each constriction. As will be apparent from the present disclosure, in some aspects, the multiple constrictions may include two or more constrictions present in a single microfluidic device (e.g., a multi-row constriction chip), such that the cells pass through the multiple constrictions in sequence. In some aspects, the multiple constrictions are part of a separate microfluidic device, such that a first constriction is associated with a first microfluidic device and a second constriction is associated with a second microfluidic device. For example, as demonstrated herein, in some aspects, the cells pass through a first constriction (i.e., a first extrusion process), which is associated with a first microfluidic device (e.g., a chip). After the cells pass through the first constriction, the cells pass through a second constriction (i.e., a second extrusion process), which is associated with a second microfluidic device (e.g., a chip). In some aspects, after passing through the first constriction, the cells are cultured in a culture medium before passing through the second constriction. In some aspects, the cells are cultured for at least about 1 minute, at least about 30 minutes, at least about 1 hour, at least about 6 hours, at least about 12 hours, or at least about 1 day prior to passing the cells through the second constriction. As will be apparent from this disclosure, in some aspects, the first and second constrictions have the same length, depth, and / or width. In some aspects, the first and second constrictions may have different lengths, depths, and / or widths.

[0156] In some aspects, after passing through the constriction, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or about 100% of the cells remain viable. In the case where cells pass through multiple constrictions (such as a portion of a single microfluidic device or a separate microfluidic device), after passing through each of the multiple constrictions, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or about 100% of the cells remain viable. Any suitable method known in the art can be used to measure the viability of cells. In some aspects, Nucleocounter NC-200, Orflo Moxi Go II cell counter or both can be used to measure the viability of cells.

[0157] Exemplary microfluidic channels containing cell deforming constrictions for use with the methods disclosed herein are described in U.S. Publication No. 2020 / 0277566A1, U.S. Publication No. 2020 / 0332243A1, U.S. Publication No. 2020 / 0316604A1, U.S. Provisional Application No. 63 / 131,423, and U.S. Provisional Application No. 63 / 131,430, each of which is incorporated herein by reference in its entirety.

[0158] In some aspects, the microfluidic channel described herein (i.e., including a constriction) includes a lumen and is configured so that cells (e.g., a cell suspension) suspended in a buffer can pass through the channel. The microfluidic channel that can be used for the present disclosure can be manufactured using any suitable material available in the art, including but not limited to silicon, metals (e.g., stainless steel), plastics (e.g., polystyrene), ceramics, glass, crystalline substrates, amorphous substrates, polymers (e.g., polymethyl methacrylate (PMMA), PDMS, cyclic olefin copolymers (COC)), or combinations thereof. In some aspects, the material is silicon. The making of microfluidic channels can be carried out by any method known in the art, including but not limited to dry etching (e.g., deep active ion etching), wet etching, photolithography, injection molding, laser ablation, SU-8 masks, or combinations thereof. In some aspects, dry etching is used for making.

[0159] In some aspects, the microfluidic channel that can be used in the present disclosure includes an inlet portion, a center point, and an outlet portion. In some aspects, the cross-section of one or more of the inlet portion, the center point, and / or the outlet portion can be changed. For example, the shape of the cross-section can be annular, elliptical, long slit, square, hexagonal, or triangular.

[0160] The inlet portion defines a contraction angle. In some aspects, by adjusting (e.g., increasing or decreasing) the contraction angle, any obstruction of the contraction portion can be reduced or prevented. In some aspects, the angle of the outlet portion can also be adjusted. For example, in some aspects, the angle of the outlet portion can be configured to reduce the possibility of turbulence that can produce non-laminar flow. In some aspects, the walls of the inlet portion and / or the outlet portion are straight. In some aspects, the walls of the inlet portion and / or the outlet portion are curved.

[0161] In some aspects, the length, depth and / or width of the constriction can be changed. In some aspects, by adjusting (e.g., increasing or decreasing) the length, depth and / or width of the constriction, the delivery efficiency of the payload can be regulated. As used herein, the term "delivery efficiency" refers to the amount of payload delivered to the cell. For example, an increase in delivery efficiency can occur when the total amount of payload delivered increases.

[0162] In some aspects, the contraction has a length of less than about 1 μm. In some aspects, the contraction has a length of about 0.1 μm to about 100 μm. In some aspects, the contraction has a length of less than about 0.1 μm, about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1 μm, about 2.5 μm, about 5 μm, about 7.5 μm, about 10 μm, about 12.5 μm, about 15 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm or about 100 μm. In some aspects, the contraction has a length of about 0.5 μm. In some aspects, the contraction has a length of about 10 μm. In some aspects, the constriction has a length of about 70 μm.

[0163] In some aspects, the constriction has a depth of about 5 μm to about 90 μm. In some aspects, the constriction has a depth greater than or equal to about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, about 100 μm, about 110 μm, or about 120 μm. In some aspects, the constriction has a depth of about 10 μm. In some aspects, the constriction has a depth of about 20 μm. In some aspects, the constriction has a depth of about 70 μm. In some aspects, the constriction has a depth of about 10 μm.

[0164] In some aspects, the constriction has a width of about 1 μm to about 10 μm. In some aspects, the constriction has a width of about 1 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2 μm, about 3 μm, about 4 μm, about 4.5 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, or about 10 μm. In some aspects, the constriction has a width of about 6 μm. In some aspects, the constriction has a length of 10 μm, a width of 6 μm, and a depth of 70 μm. In some aspects, the constriction has a width of about 3.5 μm. For example, in some aspects, a constriction useful with the present disclosure has a depth of 10 μm, a width of 3.5 μm, and a length of 70 μm.

[0165] In some aspects, the diameter of the constriction (e.g., contained within a microfluidic channel) varies with the diameter of one or more cells passing through the constriction. Without being limited by any theory, in some aspects, the diameter of the constriction is smaller than the diameter of the cell, so that a deforming force is applied to the cell as the cell passes through the constriction, thereby causing a transient physical deformation of the cell.

[0166] Thus, in some aspects, the diameter of the constriction (also referred to herein as the "constriction size") is about 20% to about 99% of the diameter of the cell. In some aspects, the constriction size is about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 99% of the diameter of the cell. As will be apparent from this disclosure, by adjusting (e.g., increasing or decreasing) the diameter of the constriction, the efficiency of payload delivery to the cell can also be modulated.

[0167] III.C.2. Surfaces with pores

[0168] In some aspects, the constriction described herein comprises pores contained in the surface. For example, non-limiting examples of pores contained in the surface that can be used in the present disclosure are described in U.S. Publication No. 2019 / 0382796A1, which is incorporated herein by reference in its entirety.

[0169] In some aspects, surfaces useful in the present disclosure (i.e., comprising one or more pores in which physical distortions can be induced when cells pass through the pores) can be made using any suitable material available in the art and / or in any of a number of forms. Non-limiting examples of such materials include synthetic or natural polymers, polycarbonates, silicon, glass, metals, alloys, nitrocellulose, silver, cellulose acetate, nylon, polyester, polyethersulfone, polyacrylonitrile (PAN), polypropylene, PVDF, polytetrafluoroethylene, mixed cellulose esters, porcelain, ceramics, or combinations thereof.

[0170] In some aspects, the surface comprises a filter. In some aspects, the filter is a tangential flow filter. In some aspects, the surface comprises a membrane. In some aspects, the surface comprises a sponge or sponge-like matrix. In some aspects, the surface comprises a matrix. In some aspects, the surface comprises a maze surface. In some aspects, the maze surface comprises cellulose acetate.

[0171] The surfaces disclosed herein (i.e., comprising one or more pores) may have any suitable shape known in the art. Where the surface has a 2-dimensional shape, the surface may be, but is not limited to, an annular, elliptical, circular, square, star-shaped, triangular, polygonal, pentagonal, hexagonal, heptagonal, or octagonal. In some aspects, the shape of the surface is circular. Where the surface has a 3-dimensional shape, in some aspects, the surface may be, but is not limited to, cylindrical, conical, or cubic.

[0172] As will be apparent from the present disclosure, surfaces (e.g., comprising one or more pores) that can be used for the present disclosure may have various cross-sectional widths and thicknesses. In some aspects, the cross-sectional width of the surface is between about 1 mm and about 1 m. In some aspects, the surface has a defined thickness. In some aspects, the surface thickness is uniform. In some aspects, the surface thickness is variable. For example, in some aspects, some parts of the surface are thicker or thinner than other parts of the surface. In such aspects, the thickness of different parts of the surface may vary by about 1% to about 90%. In some aspects, the thickness of the surface is between about 0.01 μm to about 5 mm.

[0173] The cross-sectional width of the pore may depend on the type of cells targeted by the payload. In some aspects, the pore size varies with the diameter of the cells of the cell cluster to be targeted. In some aspects, the pore size causes the cells to be disturbed (i.e., physically deformed) after passing through the pore. In some aspects, the pore size is smaller than the diameter of the cell. In some aspects, the pore size is about 20% to about 99% of the diameter of the cell. In some aspects, the pore size is about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 99% of the diameter of the cell. In some aspects, the pore size is about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about μm, about 9 μm, about 10 μm, about 11 μm, about 12 μm, about 13 μm, about 14 μm, or about 15 μm or more.

[0174] The entrance and exit of the pore can have a variety of angles. In some aspects, by adjusting (e.g., increasing or decreasing) the pore angle, any obstruction of the pore can be reduced or prevented. In some aspects, the flow rate (i.e., the rate at which cells or suspensions containing cells pass through the pore) is between about 0.001 mL / cm / second and about 100 L / cm / second. For example, the angle of the entrance or exit portion can be between about 0 degree and about 90 degrees. In some aspects, the pore has the same entrance and exit angles. In some aspects, the pore has different entrance and exit angles. In some aspects, the pore edge is smooth, such as round or curved. As used herein, a "smooth" pore edge has a continuous, flat and uniform surface without protrusions, protuberances or uneven parts. In some aspects, the pore edge is sharp. As used herein, a "sharp" pore edge has a thin edge that is pointed or acute. In some aspects, the pore is straight. As used herein, a "straight" pore does not contain curves, turns, angles or other irregular shapes. In some aspects, the duct is curved. As used herein, a "curved" duct is one that turns or deviates from a straight line. In some aspects, the duct has multiple bends, such as about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10 or more bends.

[0175] The pore can have any shape known in the art, including 2-dimensional or 3-dimensional shapes. The pore shape (e.g., cross-sectional shape) can be, but is not limited to, annular, elliptical, circular, square, star-shaped, triangular, polygonal, pentagonal, hexagonal, heptagonal, and octagonal. In some aspects, the cross section of the pore is circular. In some aspects, the 3-dimensional shape of the pore is cylindrical or conical. In some aspects, the pore has a grooved inlet and outlet shape. In some aspects, among the pores in a given surface, the pore shape is homogeneous (i.e., consistent or regular). In some aspects, among the pores in a given surface, the pore shape is inhomogeneous (i.e., mixed or changed).

[0176] Surfaces useful for the present disclosure may have a single pore. In some aspects, surfaces useful for the present disclosure include a plurality of pores. In some aspects, the pores cover about 10% to about 80% of the total surface area of ​​the surface. In some aspects, the surface contains about 1.0x10 5 to about 1.0x10 30 In some aspects, the surface comprises about 10 to about 1.0 x 10 15 A pore.

[0177] The pores can be distributed in a given surface in many ways. In some aspects, the pores are distributed in parallel in a given surface. In some aspects, the pores are distributed side by side in the same direction and are spaced the same distance in a given surface. In some aspects, the distribution of the pores is ordered or homogeneous. In such aspects, the pores can be distributed in a regular systematic pattern, or can be spaced the same distance in a given surface. In some aspects, the distribution of the pores is random or inhomogeneous. For example, in some aspects, the pores are distributed in an irregular disordered pattern, or are spaced at different distances in a given surface.

[0178] In some aspects, multiple surfaces are used so that cells pass through multiple pores, wherein the pores are located on different surfaces. In some aspects, multiple surfaces are distributed in series. Multiple surfaces can be homogeneous or heterogeneous in surface size, shape and / or roughness. Multiple surfaces can also contain pores with homogeneous or heterogeneous pore size, shape and / or number, thereby enabling a series of payloads to be delivered to different cell types simultaneously.

[0179] In some aspects, for example, individual pores of surfaces useful for the present disclosure have uniform width dimensions (i.e., a constant width along the length of the pores). In some aspects, individual pores have variable widths (i.e., a width that increases or decreases along the length of the pores). In some aspects, the pores within a given surface have the same individual pore depths. In some aspects, the pores within a given surface have different individual pore depths. In some aspects, the pores are immediately adjacent to each other. In some aspects, the pores are spaced a distance apart from each other. In some aspects, the pores are spaced a distance apart from each other of about 0.001 μm to about 30 mm.

[0180] In some aspects, the surface is coated with material. The material can be selected from any material known in the art, including but not limited to Teflon (Teflon), adhesive layer, surfactant, protein, adhesion molecule, antibody, anticoagulant, factor, nucleic acid, lipid, carbohydrate, transmembrane protein or their combination of regulating cell function. In some aspects, the surface is coated with polyvinyl pyrrolidone. In some aspects, the material is covalently attached to the surface. In some aspects, the material is non-covalently attached to the surface. In some aspects, the surface molecule is released at the cell through the pore.

[0181] In some aspects, the surface has modified chemical properties. In some aspects, the surface is hydrophilic. In some aspects, the surface is hydrophobic. In some aspects, the surface is charged. In some aspects, the surface is positively charged and / or negatively charged. In some aspects, the surface may be positively charged in some areas and negatively charged in other areas. In some aspects, the surface has an overall positive charge or an overall negative charge. In some aspects, the surface may be any of the following: smooth, electropolished, roughened, or plasma treated. In some aspects, the surface comprises zwitterions or dipole compounds. In some aspects, the surface is plasma treated.

[0182] In some aspects, the surface is contained within a larger module. In some aspects, the surface is contained within a syringe (such as a plastic or glass syringe). In some aspects, the surface is contained within a plastic filter holder. In some aspects, the surface is contained within a pipette tip.

[0183] III.D. Cell Perturbations

[0184] As described herein, when a cell passes through a constriction, it is physically deformed so that there is a disturbance (e.g., a hole, tear, cavity, hole, aperture, fracture, gap, perforation) in the cell membrane of the cell. Such disturbances in the cell membrane are transient and sufficient to deliver any of the payloads described herein into the cell. Cells have self-repair mechanisms that allow the cell to repair any damage in its cell membrane. See Blazek et al., Physiology (Bethesda) 30(6):438-48 (November 2015), which is incorporated herein by reference in its entirety. Thus, in some aspects, after a cell passes through a constriction (e.g., a microfluidic channel or aperture), the disturbance in the cell membrane can be reduced or eliminated so that the payload delivered to the cell does not leave the cell.

[0185] In some aspects, after the pressure is removed (e.g., the cell has passed through the constriction), the perturbation in the cell membrane persists for about 1.0 x 10 -9 In some aspects, the cell perturbation lasts for about 1.0 x 10 -9 In some aspects, the cell perturbation lasts for about 1.0 x 10 -9 seconds to about 1.0x10 -1 seconds, about 1.0x10 -9 seconds to about 1.0x10 -2 seconds, about 1.0x10 -9 seconds to about 1.0x10 -3 seconds, about 1.0x10 -9 seconds to about 1.0x10-4 seconds, about 1.0x10 -9 seconds to about 1.0x10 -5 seconds, about 1.0x10 -9 seconds to about 1.0x10 -6 seconds, about 1.0x10 -9 seconds to about 1.0x10 -7 seconds or about 1.0x10 -9 seconds to about 1.0x10 -8 In some aspects, the cell perturbation lasts about 1.0 x 10 -8 seconds to about 1.0x10 -1 seconds, about 1.0x10 -7 seconds to about 1.0x10 -1 seconds, about 1.0x10 -6 seconds to about 1.0x10 -1 seconds, about 1.0x10 -5 seconds to about 1.0x10 -1 seconds, about 1.0x10 -4 seconds to about 1.0x10 -1 seconds, about 1.0x10 -3 seconds to about 1.0x10 -1 seconds or about 1.0x10 -2 seconds to about 1.0x10 -1 The cellular perturbations (eg, pores or holes) formed by the methods described herein are not formed due to the assembly of polypeptide subunits to form a multimeric pore structure (such as that formed by complement or bacterial hemolysin).

[0186] In some aspects, the pressure applied to the cell transiently imparts cell membrane damage as the cell passes through the constriction, thereby allowing the material to diffuse passively through the perturbation. In some aspects, the cell is deformed or perturbed for only a short period of time, such as about 100 μs or less to minimize the chance of activating apoptotic pathways through cell signaling mechanisms, although other durations (e.g., in the range of nanoseconds to hours) are possible. In some aspects, the cell deformation lasts less than about 1.0 x 10 -9 In some aspects, the cell deformation lasts less than about 1.0 x 10 -9 In some aspects, the cell deformation lasts for about 1.0 x 10 -9 In some aspects, the cell deformation lasts for about 1.0 x 10 -9 In some aspects, the cell deformation lasts for about 1.0 x 10 -9seconds to about 1.0x10 -1 seconds, about 1.0x10 -9 seconds to about 1.0x10 -2 seconds, about 1.0x10 -9 seconds to about 1.0x10 -3 seconds, about 1.0x10 -9 seconds to about 1.0x10 -4 seconds, about 1.0x10 -9 seconds to about 1.0x10 -5 seconds, about 1.0x10 -9 seconds to about 1.0x10 -6 seconds, about 1.0x10 -9 seconds to about 1.0x10 -7 seconds or about 1.0x10 -9 seconds to about 1.0x10 -8 In some aspects, the cell deformation or perturbation lasts for about 1.0 x 10 -8 seconds to about 1.0x10 -1 seconds, about 1.0x10 -7 seconds to about 1.0x10 -1 seconds, about 1.0x10 -6 seconds to about 1.0x10 -1 seconds, about 1.0x10 -5 seconds to about 1.0x10 -1 seconds, about 1.0x10 -4 seconds to about 1.0x10 -1 seconds, about 1.0x10 -3 seconds to about 1.0x10 -1 seconds or about 1.0x10 -2 seconds to about 1.0x10 -1 In some aspects, deforming the cell comprises deforming the cell for a time in the range of about 1 μs to at least about 750 μs, but not limited thereto, such as at least about 1 μs, at least about 10 μs, at least about 50 μs, at least about 100 μs, at least about 500 μs, or at least about 750 μs.

[0187] In some aspects, the delivery of the payload to the cell is performed simultaneously with the cell passing through the contraction. In some aspects, the delivery of the payload to the cell can be performed after the cell passes through the contraction (i.e., when the disturbance of the cell membrane still exists and before the cell membrane of the cell recovers). In some aspects, the delivery of the payload to the cell is performed about several minutes after the cell passes through the contraction. In some aspects, the disturbance therein is corrected within about five minutes after the cell passes through the contraction after the cell passes through the contraction.

[0188] In some aspects, the viability of cells (e.g., stem cells or PBMCs) after passing through the constriction is about 5% to about 100%. In some aspects, the viability of cells after passing through the constriction is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%. In some aspects, about 1.0x10 -2 Cell viability can be measured from about 1.0 x 10 seconds to at least about 10 days after the cells pass through the constriction. -2 In some aspects, the cell viability is measured from about 1.0 x 10 10 cells per second after the cell passes through the constriction. -2 seconds to about 2 hours, about 1.0x10 -2 seconds to about 1 hour, about 1.0x10 -2 seconds to about 30 minutes, about 11.0x10 -2 seconds to about 1 minute, about 1.0x10 -2 seconds to about 30 seconds, about 1.0x10 -2 seconds to about 1 second or about 1.0x10 -2 In some aspects, cell viability is measured from about 1.5 hours to about 2 hours, from about 1 hour to about 2 hours, from about 30 minutes to about 2 hours, from about 15 minutes to about 2 hours, from about 1 minute to about 2 hours, from about 30 seconds to about 2 hours, or from about 1 second to about 2 hours after the cell passes through the constriction. In some aspects, cell viability is measured from about 2 hours to about 5 hours, from about 5 hours to about 12 hours, from about 12 hours to about 24 hours, or from about 24 hours to about 10 days after the cell passes through the constriction.

[0189] III.E. Delivery Parameters

[0190] As is apparent from the present disclosure, many parameters can affect the efficiency of the payload delivery to the cell using the extrusion processing method provided herein. Therefore, by adjusting (e.g., increasing or decreasing) one or more of the delivery parameters, the payload delivery to the cell can be improved. Therefore, in some aspects, the present disclosure relates to a method for increasing the payload delivery to the cell, wherein the method includes adjusting one or more parameters that allow a cell suspension to pass through a contraction, wherein the cell suspension comprises a cell colony, and wherein the one or more parameters increase the payload delivery to one or more cells in the cell colony compared to a reference parameter. As described elsewhere in the present disclosure, the payload can be contacted with the cell colony before, during, or after the extrusion force step.

[0191] In some aspects, by adjusting one or more of the delivery parameters, delivery of the payload to one or more cells is increased by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold as compared to delivery of the payload agent to the corresponding cells using reference parameters.

[0192] In some aspects, one or more delivery parameters that can be adjusted to increase the delivery efficiency of the parameter include cell density (ie, the concentration of cells present in, for example, a cell suspension), pressure, or both. Other examples of adjustable delivery parameters are provided elsewhere in this disclosure.

[0193] In some aspects, the cell density is about 1 x 10 5 cells / mL, about 2x10 5 cells / mL, about 3x10 5 cells / mL, about 4x10 5 cells / mL, about 5x10 5 cells / mL, about 6x10 5 cells / mL, about 7x10 5 cells / mL, about 8x10 5 cells / mL, about 9x10 5 cells / mL, about 1x10 6 cells / mL, about 2x10 6 cells / mL, about 3x10 6 cells / mL, about 4x10 6 cells / mL, about 5x10 6 cells / mL, about 6x10 6 cells / mL, about 7x10 6 cells / mL, about 8x10 6 cells / mL, about 9x10 6 cells / mL, about 1x10 7 cells / mL, about 2x10 7 cells / mL, about 3x10 7 cells / mL, about 4x10 7 cells / mL, about 5x10 7 cells / mL, about 6x10 7 cells / mL, about 7x10 7 cells / mL, about 8x10 7 cells / mL, about 9x10 7cells / mL, about 1x10 8 cells / mL, about 1.1x10 8 cells / mL, about 1.2x10 8 cells / mL, about 1.3x10 8 cells / mL, about 1.4x10 8 cells / mL, about 1.5x10 8 cells / mL, about 2.0x10 8 cells / mL, about 3.0x10 8 cells / mL, about 4.0x10 8 cells / mL, about 5.0x10 8 cells / mL, about 6.0x10 8 cells / mL, about 7.0x10 8 cells / mL, about 8.0x10 8 cells / mL, about 9.0x10 8 cells / mL or about 1.0x10 9 In some aspects, the cell density is between about 6 x 10 7 cells / mL and about 1.2x10 8 cells / mL.

[0194] In some aspects, the pressure is about 20psi, about 25psi, about 30psi, about 35psi, about 40psi, about 50psi, about 55psi, about 60psi, about 65psi, about 70psi, about 75psi, about 80psi, about 85psi, about 90psi, about 95psi, about 100psi, about 110psi, about 120psi, about 130psi, about 140psi, about 150psi, about 160psi, about 170psi, about 180psi, about 190psi or about 200psi or more. In some aspects, the pressure is between about 30psi and about 90psi. In some aspects, the pressure is about 20psi.

[0195] In some aspects, the specific type of device (e.g., microfluidic chip) can also have an impact on the delivery efficiency of the payload described herein. In the case of a microfluidic chip, different chips can have different constriction parameters, such as the length, depth, and width of the constriction; the entrance angle, exit angle, length, depth, and width of the approach area, etc. As described herein, such variables can affect the delivery of payloads into cells using the extrusion processing method of the present disclosure.

[0196] In some aspects, the length of the constriction is at most 100 μm. For example, in some aspects, the length is about 0 μm, about 0.1 μm, about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1 μm, about 2.5 μm, about 5 μm, about 7.5 μm, 10 μm, about 12.5 μm, about 15 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, or about 100 μm. In some aspects, the length of the constriction is less than 1 μm. In some aspects, the length of the constriction is less than about 0.1 μm, less than about 0.2 μm, less than about 0.3 μm, less than about 0.4 μm, less than about 0.5 μm, less than about 0.6 μm, less than about 0.7 μm, less than about 0.8 μm, less than about 0.9 μm, less than about 1 μm, less than about 2.5 μm, less than about 5 μm, less than about 7.5 μm, less than about 10 μm, less than about 12.5 μm, less than about 15 μm, less than about 20 μm, less than about 30 μm, less than about 40 μm, less than about 50 μm, less than about 60 μm, less than about 70 μm, less than about 80 μm, less than about 90 μm, or less than about 100 μm. In some aspects, the constriction has a length of about 10 μm. In some aspects, the constriction has a length of about 0.5 μm. In some aspects, the constriction has a length of about 70 μm. In some aspects, the constriction has a length of about 0 μm.For example, in some aspects, a microfluidic device (eg, a chip) useful for the present disclosure includes a constriction that resembles two points of a diamond coming together such that the length of the constriction is about 0 μm.

[0197] In some aspects, the width of the constriction is at most about 10 μm. In some aspects, the width of the constriction is less than about 1 μm, less than about 2 μm, less than about 3 μm, less than about 4 μm, less than about 5 μm, less than about 6 μm, less than about 7 μm, less than about 8 μm, less than about 9 μm or less than about 10 μm. In some aspects, the width is between about 1 μm and about 10 μm. In some aspects, the width is about 1 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2.0 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm or about 10 μm. In some aspects, the width of the constriction is about 6 μm. In some aspects, the constriction has a width of about 3.5 μm.

[0198] In some aspects, the depth of the constriction is at least about 1 μm. In some aspects, the depth of the constriction is at least about 1 μm, at least about 2 μm, at least about 3 μm, at least about 4 μm, at least about 5 μm, at least about 10 μm, at least about 20 μm, at least about 30 μm, at least about 40 μm, at least about 50 μm, at least about 60 μm, at least about 70 μm, at least about 80 μm, at least about 90 μm, at least about 100 μm, at least about 110 μm or at least about 120 μm. In some aspects, the depth is between about 5 μm and about 90 μm. In some aspects, the depth is about 5 μm, about 10 μm, about 15 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm or about 90 μm. In some aspects, the constriction has a depth of about 20 μm. In some aspects, the constriction has a depth of about 70 μm. In some aspects, the constriction has a depth of about 10 μm.

[0199] In some aspects, the depth is about 10 μm, the width is about 3.5 μm, and the length is about 70 μm, and the pressure is about 20 psi.

[0200] In some aspects, the constriction useful for the present disclosure comprises a width and a depth, wherein the width of the constriction is any distance described herein, and wherein the depth of the constriction is any distance described herein. In some aspects, the constriction comprises a width and a depth, wherein the width of the constriction is about 1 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, or about 10 μm, and wherein the depth of the constriction is about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, or about 90 μm. In some aspects, such a constriction may comprise a length of about 0 μm (eg, the constriction resembles two points of a diamond coming together such that the length of the constriction is about 0 μm).

[0201] Other examples of parameters that can affect the delivery of a payload to a cell include, but are not limited to, the dimensions of the constriction (e.g., length, width, and / or depth), the angle of entry of the constriction, the surface characteristics of the constriction (e.g., roughness, chemical modification, hydrophilicity, hydrophobicity), the operating flow rate, the payload concentration, the amount of time for cell recovery, or a combination thereof. Other parameters that can affect the delivery efficiency of a payload can include the velocity of the cell in the constriction, the shear rate in the constriction, the viscosity of the cell suspension, the velocity component perpendicular to the flow rate, and the time in the constriction. Such parameters can be designed to control the delivery of a payload.

[0202] In some aspects, the temperature used in the methods of the present disclosure may also have an effect on the efficiency of payload delivery to the cells and the viability of the cells. In some aspects, the extrusion processing method is performed between about -5°C and about 45°C. For example, the method may be performed at room temperature (e.g., about 20°C), physiological temperature (e.g., about 37°C), above physiological temperature (e.g., greater than about 37°C to 45°C or higher), or low temperature (e.g., about -5°C to about 4°C), or at a temperature between these exemplary temperatures.

[0203] Various methods can be used to drive cells through the contraction. For example, pressure can be applied by a pump (e.g., a gas cylinder or a compressor) on the inlet side, a vacuum can be applied by a vacuum pump on the outlet side, capillary action can be applied by a tube, and / or the system can be gravity fed. A displacement-based flow system (e.g., a syringe pump, a peristaltic pump, a manual syringe or a pipette, a piston, etc.) can also be used. In some aspects, cells are passed through the contraction by positive pressure. In some aspects, cells are passed through the contraction by constant pressure or variable pressure. In some aspects, pressure is applied using a syringe. In some aspects, pressure is applied using a pump. In some aspects, the pump is a peristaltic pump or a diaphragm pump. In some aspects, pressure is applied using a vacuum. In some aspects, cells are passed through the contraction by gravity. In some aspects, cells are passed through the contraction by capillary pressure.

[0204] In some aspects, the fluid flow guides the cells through the constriction. In some aspects, before the cells pass through the constriction, the fluid flow is turbulent. Turbulence is a fluid flow in which the magnitude and direction of the velocity at a given point varies irregularly. In some aspects, the fluid flow through the constriction is laminar. Laminar flow involves the uninterrupted flow of a fluid near a solid boundary, wherein the direction of flow at each point remains constant. In some aspects, after the cells pass through the constriction, the fluid flow is turbulent. The velocity of the cells through the constriction may vary. In some aspects, the cells pass through the constriction at a uniform cell velocity. In some aspects, the cells pass through the constriction at a fluctuating cell velocity.

[0205] In some aspects, a combined treatment is used to deliver a payload, such as the method described herein, which is subsequently exposed to an electric field downstream of the contraction. In some aspects, after passing through the contraction, the cell passes through an electric field generated by at least one electrode. In some aspects, the electric field helps deliver the payload to a second location inside the cell, such as a nucleus. In some aspects, one or more electrodes are close to the cell deformation contraction to generate an electric field. In some aspects, the electric field is between about 0.1kV / m and about 100MV / m. In some aspects, an integrated circuit is used to provide an electrical signal to drive the electrode. In some aspects, the cell is exposed to an electric field for a pulse width between about 1ns and about 1s and a time between about 100ns and about 10s.

[0206] III.F. Therapeutic Uses

[0207] In some aspects, the present disclosure relates to the use of modified HSC produced using the extrusion processing method described herein for treating various diseases or conditions. As is apparent from the present disclosure, the methods and compositions provided herein can be used for diseases and conditions for which cell replacement therapy can be used as treatment. By replacing damaged cells with cells produced using the methods provided herein, in some aspects, one or more functions associated with damaged cells can be restored, and thereby treating diseases or conditions. For example, in some aspects, a subject suffering from a blood disorder (e.g., a hemoglobinopathy) can be administered a modified HSC produced using the extrusion processing method provided herein. The administration of such HSC can be used to improve one or more symptoms associated with a blood disorder. Non-limiting examples of blood disorders that can be treated using the methods provided herein include sickle cell disease (SCD), thalassemia syndrome, severe aplastic anemia, Fanconi anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, congenital amegakaryocytic thrombocytopenia, or a combination thereof. In some aspects, diseases or conditions that can be treated using the present disclosure include immune disorders. Non-limiting examples of immune disorders include severe combined immunodeficiency, Wieder-Oberleukodystrophy, or both. In some aspects, the diseases or disorders treatable by the present disclosure include metabolic disorders. Non-limiting examples of metabolic disorders include Krabbe disease (GLD), Hurler syndrome, adrenoleukodystrophy, metachromatic leukodystrophy, Fabry disease, Gaucher disease, cystinosis, Hunter syndrome, Pompe disease, or a combination thereof.

[0208] As is apparent from this disclosure, the therapeutic methods provided herein can be used without pre-treating the subject to be treated (e.g., using toxic myeloablative therapy, such as administration of busulfan) compared to other HSC-based treatments available in the art. Non-limiting examples of such myeloablative pre-treatment regimens include: irradiation, chemotherapy, small molecules, antibodies, or a combination thereof. As described herein, by using mobilization factors (e.g., plerixafor) and / or apoptosis factors (e.g., venetola) that are not associated with any adverse side effects, the therapeutic methods provided herein allow for a much safer and more efficient method to promote implantation of therapeutically modified HSCs.

[0209] IV. Compositions of the Disclosure

[0210] In some aspects, the present disclosure provides a system for delivering a payload to cells (e.g., HSCs), the system comprising a microfluidic channel as described herein, a cell suspension comprising a plurality of cells, and a payload; wherein the constriction is configured to allow the plurality of cells to pass through the microfluidic channel, wherein the passage of the plurality of cells causes distortion and disruption of the cell membranes of the cells, thereby allowing the payload to enter the cells.

[0211] In some aspects, the present disclosure provides a system for delivering a payload, the system comprising a surface with pores, a cell suspension comprising a plurality of cells, and a payload; wherein the surface with pores is configured so that a plurality of cells can pass through the pores, wherein the passage of a plurality of cells causes distortion and destruction of the cell membrane of the cell, thereby allowing the payload to enter the cell. In some aspects, the surface is a filter or a membrane. In some aspects of the above aspects, the system further comprises at least one electrode to generate an electric field. In some aspects, the system is used to deliver the payload to the cell by any of the methods described herein. The system may include any of the aspects described in the methods disclosed above, including a microfluidic channel or a surface with pores to provide a cell deformation contraction, a cell suspension, a cell disturbance, and a delivery parameter. In some aspects, delivery parameters (such as operating flow rate, cell and compound concentration, cell velocity in the contraction, and the composition of the cell suspension (e.g., osmotic pressure, salt concentration, serum content, cell concentration, pH value, etc.)) are optimized to deliver the payload to the cell.

[0212] In some aspects, the disclosure provides a cell (e.g., HSC) produced using any one of the methods provided herein. In some aspects, a cell comprising a disturbance in a cell membrane is provided herein, wherein the disturbance is due to one or more parameters, and the one or more parameters deform the cell (e.g., delivery parameters described herein), so as to form a disturbance in the cell membrane of the cell, so that a payload can enter the cell. In some aspects, a cell comprising a payload is provided herein, wherein the payload enters the cell by the disturbance in the cell membrane, and the disturbance is due to one or more parameters, and the one or more parameters deform the cell (e.g., delivery parameters described herein) and so as to form a disturbance in the cell membrane of the cell, so that the payload enters the cell. In some aspects, such cells may include the modified HSC described herein (e.g., showing increased resistance to mobilization and / or apoptotic factors).

[0213] In some aspects, the disclosure provides a composition comprising a plurality of cells, wherein the plurality of cells are produced by any of the methods provided herein. Also provided herein is a composition comprising a cell population and a payload under one or more parameters, wherein the one or more parameters cause one or more cells in the cell population to deform and thereby form a perturbation in the cell membrane of the one or more cells, and wherein the perturbation in the cell membrane allows the payload to enter the one or more cells.

[0214] In some aspects, the disclosure also provides a composition comprising a colony of modified hematopoietic stem cells (HSC), wherein the modified HSC comprises a payload, which can: (i) increase the resistance of the modified HSC to mobilization factors, (ii) increase the resistance of the modified HSC to inhibitors of anti-apoptotic factors, (iii) increase the resistance of the modified HSC to exhaustion factors, (iv) increase the expression of homing factors on modified HSC, or (v) a combination thereof. As further described elsewhere in the disclosure, in some aspects, the payload is delivered to HSC using a method other than the extrusion processing delivery method provided herein. The disclosure provides non-limiting examples of such methods elsewhere.

[0215] Also provided is a medicine box or article for delivering a payload as described herein to a cell. In some aspects, the medicine box is contained in a composition described herein (e.g., a microfluidic channel or a surface containing pores, a cell suspension, and / or a payload) in a suitable package. Suitable packaging materials are known in the art, and include, for example, vials (such as sealed vials), containers, ampoules, bottles, jars, flexible packaging (e.g., sealed polyester film or plastic bags), etc. These articles can be further sterilized and / or sealed.

[0216] The present disclosure also provides kits comprising the components of the methods described herein and may also include instructions for performing the methods to deliver a payload into a cell. The kits described herein may also include other materials, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any of the methods described herein; e.g., instructions for delivering a payload into a cell.

[0217] The following examples are offered by way of illustration and not by way of limitation.

[0218] Example

[0219] Example 1: Analysis of the Effect of Extrusion Processing on HSC Implantation Efficiency

[0220] To assess any potential effects on engraftment efficiency, CD34+ HSCs were loaded with mRNA encoding GFP using the extrusion processing method provided herein and adoptively transferred into NSG and NBSGW recipient mice. The specific methods used are provided below.

[0221] Extrusion Processing

[0222] Put two 5M (ie 5x 10 6 ) Cell vials were thawed and diluted with FACS buffer. Cells were centrifuged at 400rcf at room temperature to 2M / ml. Cells were transferred to 12-well untreated plates and cultured overnight at 37°C in complete CD34+ culture medium. Supernatant was drawn off and cells were resuspended with 3ml of CD34+ culture medium. Cells were diluted to 2M / ml, spread, and cultured overnight at 37°C. Cells were prepared for extrusion processing. Table 5 provides a description of the different test groups and the specific cell suspension solutions used for extrusion processing.

[0223] Table 5. Cell suspension solution for extrusion processing

[0224]

[0225] As shown in Table 5, under 20psi, use microfluidic constriction (10 μm is dark, 3.5 μm is wide, and 70 μm is long) do not use mRNA to carry out extrusion processing to group A and C at room temperature.Then cell is transferred to the 15ml conical flask containing 5mL CD34+ culture medium.Under 20psi, use microfluidic constriction (10 μm is dark, 3.5 μm is wide, and 70 μm is long) at room temperature use GFMmRNA to carry out extrusion processing to group B and D.Cell is transferred to the 15ml conical flask containing 5mL CD34+ culture medium.At room temperature, the cell from different groups is centrifuged separately 5 minutes under 500rcf.Supernatant is extracted and cell is resuspended in the sterile PBS of 1mL.

[0226] Adoptive transfer

[0227] All mice underwent tail vein injection. Each mouse received a 100 ul injection containing 250K HSC cells according to the groups specified above.

[0228] Bone marrow harvest and analysis

[0229] Six weeks after the injection, all mice were harvested from the femur and tibia of each mouse. Tibia and femur were cut near the knee joint and placed in a microcentrifuge tube. 25 μL FAC buffer was added in the Eppendorf tube and the microcentrifuge tube containing the sample was placed inside. Sample was centrifuged for 15 seconds under 10,000rcf. Then the ACK lysis buffer of 2ml was used to process 1-2min to remove red blood cells. After the dissolution, washed cells and used FACs buffer to resuspend.

[0230] Spleen harvest and analysis

[0231] Six weeks after the injection, spleen was collected from all mice and each was placed in the Ai Ben De tube containing 1ml FACs buffer. Each spleen sample was crushed to a 50ml conical flask by a 70 μm filter. Sample was rinsed with 10ml FACs buffer. Sample was centrifuged for 5 minutes at 400rcf and then resuspended in 2ml ACK buffer. Sample was incubated for 1-2 minute and then 10ml FACs buffer was used to stop the reaction. Sample was then filtered through a 70 μm filter, washed, and then resuspended in the FACs buffer.

[0232] Peripheral blood harvest

[0233] Six weeks after the injection, blood was collected from all mice. Each blood sample was diluted with PBS (1:1), then layered on the top of the Ficoll Paque of 500ul. Cells were centrifuged for 25min at room temperature under 800rcf and the white blood cells collected at the interface between Ficoll and the water layer. These cells were washed and then resuspended in 0.5ml FACs buffer.

[0234] FACS analysis

[0235] 2 to 5 million cells were centrifuged at 400 rcf for 4 minutes at room temperature. The supernatant was discarded and the cells were resuspended in 200 μL of L / D NIR (1:200 dilution) and FC blocker (1:50 dilution). The cells were then stained with anti-human CD45 and anti-mouse CD45 antibodies. The ratio of human CD45 cells to mouse CD45 cells was then analyzed using an Attune flow cytometer.

[0236] result

[0237] like Figure 1 and Figure 2C As shown in , extruded HSCs showed no deleterious effects on their engraftment potential. A significant percentage of adoptively transferred extruded human HSCs was observed in the bone marrow of NSG and NBSGW mice. Figure 2A ) and spleen ( Figure 2B ) were observed in .

[0238] These results confirm that the extrusion processing method presented here does not have any negative impact on the engraftment potential of HSCs.

[0239] Example 2: Analysis of CXCR4 and Bcl-2 overexpression after extrusion

[0240] To evaluate whether expression of certain payloads described herein would help promote HSC engraftment, CD34+ HSCs were loaded with mRNA encoding CXCR4 variants or Bcl-2 using the extrusion processing methods provided herein. The specific methods used are provided below.

[0241] Extrusion

[0242] One 5M cell vial was thawed and diluted with FACs buffer. Cells were centrifuged at 400 rcf at room temperature, then washed and incubated in complete CD34+ medium (StemSpan TM The cells were resuspended in SFEMII (containing 100 ng / ml SCF, TPO, Fl t3-L) to 2 M / ml. The cells were transferred to a 12-well untreated plate and cultured at 37° C. To expand HSC, the cells were cultured in complete CD34+ medium for 4 days.

[0243] The cells were prepared for extrusion processing. The cells were counted, washed and the concentration was adjusted to 10 M / mL by adding OptiMem. The following buffer solutions were prepared for each sample as shown in Table 6:

[0244] Table 6. Cell suspension solution for extrusion processing

[0245]

[0246] As shown in Table 6 above, Group A was used as a control (i.e., not in contact with any payload and not extruded). Group B was extruded without any payload at room temperature using a microfluidic constriction (10 μm deep, 3.5 μm wide, and 70 μm long) at 30 psi. Groups CH were extruded at room temperature using one of the payloads shown above, i.e., Group C: wild-type CXCR4 mRNA; Group D: CXCR4-A175F variant mRNA; Group E: CXCR4-R334X+A175F variant mRNA; Group F: CXCR4-R334X variant mRNA; Group G: wild-type Bcl-2 mRNA; and Group H: Bcl-2-G101V variant mRNA. Groups CH were extruded using the same conditions as in Group B (i.e., microfluidic constriction: 10 μm deep, 3.5 μm wide, and 70 μm long; at 30 psi).

[0247] Subsequently, cells from each of groups AH were transferred individually to their own 5 ml conical flasks containing 2 mL of CD34+ culture medium. Cells from all groups were centrifuged individually at room temperature at 500 rcf for 5 minutes. The supernatant was withdrawn and the cell colonies were individually resuspended in 1 mL of CD34+ culture medium and cultured at 37°C for 72 hours.

[0248] FACS analysis

[0249] At 4, 24, 48 and 72 hours, 200ul of cells were extracted and centrifuged at room temperature at 400rcf for 4 minutes. Supernatant was discarded and cells were resuspended in 50 μL of L / D aqua (1:200 dilution in FACs buffer) and Fc blocker (1:50 dilution in FACs buffer). Cells were incubated in the dark for 20 minutes at room temperature, and cells were centrifuged at room temperature at 400rcf for 4 minutes. Then cells were incubated with fluorescent anti-human CXCR4 antibody at 4C for 30 minutes. After incubation, 200 μL of FACs separation buffer was added to each sample and the sample was centrifuged at 400rcf for 4 minutes. Then cells were fixed with paraformaldehyde for 20 minutes, then stained with fluorescent anti-human BCL2 antibody for 30min at room temperature. Supernatant was discarded and cells were resuspended with 200 μL of FACs separation buffer. Then Attune flow cytometer was used to analyze cells.

[0250] result

[0251] like Figure 3A , Figure 3B , Figure 4A as well as Figure 4BAs shown in , extrusion processing induced high expression of the delivered mRNA. As measured in vitro, all CXCR4 variants showed expression above background for at least 48 hours ( Figure 3A and Figure 3B ). In addition, Figure 3C As shown in, CD34+HSCs extruded with the CXCR4-A175F variants exhibited increased resistance to plerixafor (i.e., mobilization factor) (demonstrated by CXCL12 signaling) compared to corresponding CD34+HSCs extruded with wild-type CXCR4 mRNA. Without being limited by any theory, such results suggest that modified HSCs will be more resistant to the effects of mobilization factors (which promote mobilization of cells from the bone marrow to the peripheral blood) and thereby allow for improved implantation within the bone marrow. Finally, all BCL2 variants also showed expression above background for at least 72 hours ( Figure 4A and Figure 4B ).

[0252] In summary, the results provided herein demonstrate that HSCs with enhanced engraftment capacity can be generated using the extrusion processing methods provided herein.

[0253] Example 3: In vivo analysis of CXCR4 expression in extruded CD34+ HSCs

[0254] To further evaluate whether modifying HSCs to express certain homing receptors would allow for improved engraftment in the bone marrow, human CD34+ HSCs were cultured overnight and prepared for extrusion as generally described in Example 1. Figure 3D As shown in , CD34+ HSCs were extruded without payload (extrusion alone) or with mRNA encoding wild-type CXCR4 and then adoptively transferred into NSG mice. Approximately 24 hours later, mice were sacrificed and CXCR4 expression in the bone marrow was assessed.

[0255] like Figure 3E As shown in , significantly higher CXCR4 expression was observed in the bone marrow of animals receiving HSCs processed using CXCR4 mRNA extrusion compared to those receiving HSCs processed without mRNA extrusion. These results confirm the in vivo expression of CXCR4 in HSCs processed using CXCR4 mRNA extrusion after adoptive transfer. Such results further confirm that the extrusion processing methods provided herein can be used to modify HSCs to express certain homing receptors (e.g., CXCR4) so ​​that the modified HSCs exhibit improved homing to the bone marrow, which can allow for improved implantation.

[0256] Example 4: In vivo analysis of Bcl-2 expression in extruded CD34+ HSCs

[0257] To further evaluate the effects of the survival factors described herein on HSC engraftment, human CD34+ HSCs were cultured overnight and prepared for extrusion as generally described in Example 1. Figure 5A As shown in, CD34+ HSCs were extruded using control mRNA or mRNA encoding a Bcl-2 variant (i.e., G101V) and then adoptively transferred into NSG mice. Approximately 24 hours later, mice were sacrificed and the engraftment of the transferred HSCs in the bone marrow was assessed by measuring Bcl-2 expression using flow cytometry.

[0258] like Figure 5B As shown in , there was minimal Bcl-2 expression in the bone marrow of mice that received HSCs processed with control mRNA extrusion. In contrast, significant Bcl-2 expression was observed in the bone marrow of mice that received CD34+ HSCs modified to contain Bcl-2 variant mRNA, demonstrating that these cells are able to express Bcl-2 in vivo.

[0259] These results further demonstrate that the survival factors described herein (eg, Bcl-2 G101V) can be used to enhance engraftment of HSCs, for example, when delivered to HSCs using the extrusion processing methods described herein.

[0260] Example 5: Analysis of resistance of CD34+ HSCs containing Bcl-2 variant mRNA to apoptotic factors

[0261] As described herein, modified HSCs of the present disclosure (e.g., extruded to include survival factors, such as Bcl-2 variants) exhibit increased resistance to various apoptotic factors. To further demonstrate such improved properties, human CD34+ HSCs were cultured overnight and prepared for extrusion as generally described in Example 1. Fig. 6A As shown in Figure , CD34+ HSCs were isolated and labeled with different fluorescent markers ( Purple or The cells labeled with a far-infrared (Far Infrared) marker were then extruded using GFP mRNA, and cells labeled with a far-infrared fluorescent marker were extruded using mRNA encoding a Bcl-2 variant (i.e., G101V). The cells from each group were mixed 1:1 and then adoptively transferred into NSG mice. Some mice were also given Bcl-2 and MCL-1 inhibitors (i.e., Venetoclax and S63845, respectively) (i.e., inhibitors of anti-apoptotic factors). About 24 hours after the transfer, the mice were sacrificed and the implantation of transformed cells in the bone marrow was evaluated.

[0262] like Figure 6BAs shown in , in the bone marrow of mice administered an apoptotic factor, the frequency of transferred HSCs modified to contain Bcl-2 variant mRNA was significantly greater than the frequency of transferred HSCs modified to contain GFP mRNA.

[0263] These results demonstrate that the modified HSCs disclosed herein have an enhanced ability to resist the effects of anti-apoptotic inhibitors. In addition, without being limited by any one theory, the results also indicate that the combination of anti-apoptotic inhibitors and the modified HSCs described herein are particularly useful for enhancing engraftment by selectively depleting unmodified endogenous HSCs from the bone marrow and allowing for improved engraftment of the transferred modified HSCs.

[0264] Incorporated by Reference

[0265] All publications, patents, patent applications, and other documents cited in this application are incorporated herein by reference in their entirety for all purposes, to the same extent as if each individual publication, patent, patent application, or other document was individually indicated to be incorporated by reference for all purposes.

[0266] Equivalent

[0267] Although various specific aspects have been illustrated and described, the above description is not restrictive. It should be understood that various changes can be made without departing from the spirit and scope of the present disclosure. Many changes will become apparent to those skilled in the art after reviewing this specification.

Claims

1. A method for producing modified hematopoietic stem cells (HSCs), the method comprising passing a cell suspension comprising a population of HSCs through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSC, and wherein the payload is capable of modifying the HSC such that the HSC exhibits: (i) increased resistance to mobilization factors, (ii) increased resistance to apoptotic factors, (iii) increased resistance to depletion factors, (iv) increased expression of homing factors, or (v) a combination thereof.

2. The method of claim 1, wherein after the modification, the resistance of the HSC to the mobilization factor is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

3. The method of claim 1 or 2, wherein after the modification, the resistance of the HSC to the apoptotic factor is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

4. The method of any one of claims 1 to 3, wherein after the modification, the resistance of the HSC to the depletion factor is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

5. The method of any one of claims 1 to 4, wherein the expression of a homing factor on the HSC is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

6. A method for increasing the homing of hematopoietic stem cells (HSCs) to the bone marrow of a subject in need thereof, the method comprising passing a cell suspension comprising the HSCs through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSC, and wherein the payload is capable of modifying the HSC such that the HSC exhibits increased homing to the bone marrow when administered to the subject.

7. The method of claim 6, wherein following said modification, said HSC exhibits increased expression of a homing receptor.

8. The method of claim 7, wherein the expression of the homing receptor on the HSC is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

9. A method of increasing the survival of hematopoietic stem cells in a subject in need thereof, the method comprising passing a cell suspension comprising said HSCs through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSC, and wherein the payload is capable of modifying the HSC such that the HSC exhibits increased survival when administered to the subject.

10. The method of claim 9, wherein after said modification, said HSC exhibits increased resistance to apoptotic factors.

11. The method of claim 10, wherein the resistance of the HSC to the apoptotic factor is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

12. A method of causing hematopoietic stem cells (HSCs) to engraft into the bone marrow of a subject in need thereof, the method comprising passing a cell suspension comprising the HSCs through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSC, and wherein the payload is capable of modifying the HSC such that the HSC engrafts in the bone marrow of the subject when administered to the subject.

13. The method of claim 12, wherein after the modification, the HSC exhibits: (i) increased resistance to mobilization factors, (ii) increased resistance to apoptotic factors, (iii) increased resistance to depletion factors, (iv) increased expression of homing factors, or (v) a combination thereof.

14. The method of claim 13, wherein the resistance of the HSC to the mobilization factor is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

15. The method of claim 13 or 14, wherein the resistance of the HSC to the apoptotic factor is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

16. The method of any one of claims 13 to 15, wherein the resistance of the HSC to the depletion factor is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

17. The method of any one of claims 13 to 16, wherein the expression of the homing factor on the HSC is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that did not pass through the constriction under the one or more parameters.

18. A method for producing a modified hematopoietic stem cell (HSC), the method comprising delivering a payload intracellularly to the HSC, wherein the payload is capable of modifying the HSC such that the HSC exhibits: (i) increased resistance to mobilization factors, (ii) increased resistance to apoptotic factors, (iii) increased resistance to depletion factors, (iv) increased expression of homing factors, or (v) a combination thereof.

19. A method of increasing hematopoietic stem cell (HSC) homing to the bone marrow of a subject in need thereof, the method comprising delivering a payload intracellularly to the HSC, wherein the payload is capable of modifying the HSC such that the HSC exhibits increased homing to the bone marrow when administered to the subject.

20. A method of increasing the survival of hematopoietic stem cells (HSCs) in a subject in need thereof, the method comprising delivering a payload intracellularly to the HSCs, wherein the payload is capable of modifying the HSCs such that the HSCs exhibit increased survival when administered to the subject.

21. A method of causing hematopoietic stem cells (HSCs) to engraft in the bone marrow of a subject in need thereof, the method comprising delivering a payload intracellularly to the HSCs, wherein the payload is capable of modifying the HSCs such that the HSCs engraft in the bone marrow of the subject when administered to the subject.

22. The method of any one of claims 1 to 21, wherein the payload is transiently expressed in the HSC.

23. The method of any one of claims 1 to 22, wherein the payload comprises a homing receptor, a cytokine, a growth factor, a cell adhesion molecule, a proliferation agent, a survival factor, a combination thereof, or a modulator thereof.

24. The method of claim 23, wherein the homing receptor comprises CXCR4, CXCR2, or both.

25. The method of claim 24, wherein the CXCR4 comprises an amino acid sequence that differs from the corresponding wild-type amino acid sequence shown in SEQ ID NO:

1.

26. The method of claim 25, wherein the amino acid sequence of the CXCR4 comprises one of the following mutations: R334X, A175F, H113A, D171N, D262N, I284A, H281A, Q200W, Q200A, or a combination thereof.

27. The method of any one of claims 23 to 26, wherein the cytokine comprises stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), or both.

28. The method of any one of claims 23 to 27, wherein the growth factor comprises thrombopoietin (TPO).

29. The method of any one of claims 23 to 28, wherein the cell adhesion molecule comprises an integrin, a selectin, or both.

30. The method of claim 29, wherein the cell adhesion molecule comprises VLA-4, VLA-5, LFA-1, or a combination thereof.

31. The method of any one of claims 23 to 30, wherein the proliferation agent comprises an activator of a signaling pathway involved in cell proliferation.

32. The method of claim 31, wherein the signaling pathway comprises PI3K-ATK, Ras-ERK, or both.

33. The method of any one of claims 23 to 32, wherein the survival factor comprises Bcl-2, Bcl-xL, MCL-1, Ced-9, bfl-1, or a combination thereof.

34. The method of claim 33, wherein the Bcl-2 comprises an amino acid sequence that differs from the corresponding wild-type amino acid sequence shown in SEQ ID NO:

9.

35. The method of claim 34, wherein the amino acid sequence of the Bcl-2 comprises a G101V mutation, a D103Y mutation, or both.

36. The method of any one of claims 23 to 35, wherein the modulating agent is capable of increasing the expression and / or activity of the homing receptor, the cytokine, the growth factor, the cell adhesion molecule, the proliferator, the survival factor, or a combination thereof.

37. The method of claim 36, wherein the modulator comprises a prostaglandin (eg, prostaglandin E2 (PGE2)).

38. The method of any one of claims 23 to 37, wherein the modulating agent is capable of reducing or preventing (e.g., knocking down) the activity of an inhibitor of the homing receptor, the cytokine, the growth factor, the cell adhesion molecule, the proliferator, the survival factor, or a combination thereof.

39. The method of claim 38, wherein the inhibitor comprises GPRASP1 / 2, CD26, or both.

40. The method of any one of claims 1 to 5, 13 to 18, and 22 to 39, wherein the mobilization factor comprises plerixafor, AMD3465, GROβ, G-CSF, an anti-CD117 antibody, or a combination thereof.

41. The method of any one of claims 1 to 5, 10, 11, 13 to 18, and 22 to 40, wherein the apoptotic factor comprises a Bcl-2 inhibitor (e.g., venetoclax), an MCL-1 inhibitor (e.g., S63845 or S64315), a BCL-XL inhibitor, or a combination thereof.

42. The method of any one of claims 1 to 41, wherein the payload comprises a nucleic acid.

43. The method of claim 42, wherein the nucleic acid comprises DNA, RNA, or both.

44. The method of claim 43, wherein the RNA comprises mRNA, siRNA, miRNA, lncRNA, tRNA, shRNA, self-amplifying mRNA (saRNA), PNA, locked nucleic acid (LNA), or a combination thereof.

45. The method of any one of claims 1 to 44, comprising contacting the HSC with the payload at a time: (i) before the cell suspension passes through the constriction, (ii) during the passage of the cell suspension through the constriction, (iii) after the cell suspension passes through the constriction, or (iv) a combination thereof.

46. ​​The method of claim 45, wherein the HSCs are contacted with the payload prior to the cell suspension passing through the constriction.

47. The method of claim 45 or 46, wherein the HSCs are contacted with the payload during passage of the cell suspension through the constriction.

48. The method of any one of claims 45 to 47, wherein the HSCs are contacted with the payload after the cell suspension passes through the constriction.

49. The method of any one of claims 1 to 48, wherein the HSC is CD34+, CD90+, CD45RA-, and lineage marker negative (e.g., CD2, CD3, CD11b, CD11c, CD14, CD16, CD19, CD24, CD56, CD66b, and CD235).

50. The method of any one of claims 1 to 17 and 22 to 49, wherein the constriction is within a microfluidic chip.

51. A method as described in any one of claims 1 to 17 and 22 to 50, wherein the one or more parameters are selected from cell density; pressure; length, width and / or depth of the constriction; diameter of the constriction; diameter of the cells; temperature; entrance angle of the constriction; exit angle of the constriction; length, width and / or width of the approach zone; surface properties of the constriction (e.g., roughness, chemical modification, hydrophilicity, hydrophobicity); operating flow rate; payload concentration; viscosity, osmotic pressure, salt concentration, serum content and / or pH of the cell suspension; time in the constriction; shear rate in the constriction; type of payload or a combination thereof.

52. The method of claim 51, wherein the cell density is at least about 1 x 10 5 cells / mL, at least about 2x10 5 cells / mL, at least about 3x 10 5 cells / mL, at least about 4 x 10 5 cells / mL, at least about 5x 10 5 cells / mL, at least about 6 x 10 5 cells / mL, at least about 7 x 10 5 cells / mL, at least about 8 x 10 5 cells / mL, at least about 9x10 5 cells / mL, at least about 1x 10 6 cells / mL, at least about 2x 10 6 cells / mL, at least about 3x 10 6 cells / mL, at least about 4 x 10 6 cells / mL, at least about 5 x 10 6 cells / mL, at least about 6 x 10 6 cells / mL, at least about 7x10 6 cells / mL, at least about 8 x 10 6 cells / mL, at least about 9 x 10 6 cells / mL, at least about 1x 10 7 cells / mL, at least about 2x 10 7 cells / mL, at least about 3x 10 7 cells / mL, at least about 4 x 10 7 cells / mL, at least about 5x10 7 cells / mL, at least about 6 x 10 7 cells / mL, at least about 7 x 10 7 cells / mL, at least about 8 x 10 7 cells / mL, at least about 9 x 10 7 cells / mL, at least about 1x 10 8 cells / mL, at least about 1.1 x 10 8 cells / mL, at least about 1.2 x 10 8 cells / mL, at least about 1.3 x 10 8 cells / mL, at least about 1.4 x 10 8 cells / mL, at least about 1.5x10 8 cells / mL, at least about 2.0 x 10 8 cells / mL, at least about 3.0 x 10 8 cells / mL, at least about 4.0 x 10 8 cells / mL, at least about 5.0 x 10 8 cells / mL, at least about 6.0 x 10 8 cells / mL, at least about 7.0 x 10 8 cells / mL, at least about 8.0 x 10 8 cells / mL, at least about 9.0 x 10 8 cells / mL or at least about 1.0 x 10 9 cells / mL or greater.

53. The method of claim 51 or 52, wherein the pressure is at least about 20 psi, at least about 25 psi, at least about 30 psi, at least about 35 psi, at least about 40 psi, at least about 45 psi, at least about 50 psi, at least about 55 psi, at least about 60 psi, at least about 65 psi, at least about 70 psi, at least about 75 psi, at least about 80 psi, at least about 85 psi, at least about 90 psi, at least about 95 psi, at least about 100 psi, at least about 110 psi, at least about 120 psi, at least about 130 psi, at least about 140 psi, or at least about 150 psi.

54. The method of any one of claims 51 to 53, wherein the diameter of the constriction is about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 99% of the diameter of the HSC.

55. The method of any one of claims 51 to 54, wherein the length of the constriction is at most about 100 μm.

56. A method as claimed in claim 55, wherein the length of the constriction is less than about 0.1 μm, less than about 0.2 μm, less than about 0.3 μm, less than about 0.4 μm, less than about 0.5 μm, less than about 0.6 μm, less than about 0.7 μm, less than about 0.8 μm, less than about 0.9 μm, less than about 1 μm, less than about 2.5 μm, less than about 5 μm, less than about 7.5 μm, less than about 10 μm, less than about 12.5 μm, less than about 15 μm, less than about 20 μm, less than about 30 μm, less than about 40 μm, less than about 50 μm, less than about 60 μm, less than about 70 μm, less than about 80 μm, less than about 90 μm or less than about 100 μm.

57. A method as claimed in claim 55, wherein the length of the contraction portion is about 0.1 μm, about 0.2 μm, about 0.3 μm, about 0.4 μm, about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1 μm, about 2.5 μm, about 5 μm, about 7.5 μm, about 10 μm, about 12.5 μm, about 15 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm or about 100 μm.

58. The method of any one of claims 51 to 57, wherein the width of the constriction is at most about 10 μm.

59. The method of claim 58, wherein the width of the constriction is less than about 1 μm, less than about 2 μm, less than about 3 μm, less than about 4 μm, less than about 5 μm, less than about 6 μm, less than about 7 μm, less than about 8 μm, less than about 9 μm, or less than about 10 μm.

60. The method of claim 58, wherein the width of the constriction is between about 1 μm and about 10 μm.

61. A method as claimed in claim 58, wherein the width of the constriction is about 1 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm or about 10 μm.

62. The method of any one of claims 51 to 61, wherein the depth of the constriction is at least about 1 μm.

63. A method as claimed in claim 62, wherein the depth of the constriction is at least about 2 μm, at least about 3 μm, at least about 4 μm, at least about 5 μm, at least about 10 μm, at least about 20 μm, at least about 30 μm, at least about 40 μm, at least about 50 μm, at least about 60 μm, at least about 70 μm, at least about 80 μm, at least about 90 μm, at least about 100 μm, at least about 110 μm or at least about 120 μm.

64. The method of claim 62, wherein the depth of the constriction is from about 5 μm to about 90 μm.

65. The method of claim 62, wherein the depth is about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, or about 90 μm.

66. A method as described in any one of claims 50 to 53, wherein the constriction comprises a width and a depth, wherein the width of the constriction is about 1 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm or about 10 μm, and wherein the depth of the constriction is about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm or about 90 μm.

67. The method of any one of claims 45 to 66, wherein the HSC is contacted with a plurality of payloads at the following times: (i) before the cell suspension passes through the constriction, (ii) during the passage of the cell suspension through the constriction, (iii) after the cell suspension passes through the constriction, or (iv) a combination thereof, such that passage of the cell suspension through the constriction under the one or more parameters allows at least two or more of the plurality of payloads to enter the HSC.

68. The method of claim 67, wherein the plurality of payloads comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 or more payloads.

69. The method of claim 67 or 68, wherein the at least two or more of the plurality of payloads enter the cell in parallel.

70. The method of claim 67 or 68, wherein the at least two or more of the plurality of payloads enter the cell sequentially.

71. The method of any one of claims 1 to 70, comprising passing the cell suspension through a plurality of constrictions.

72. The method of claim 71, wherein the plurality of constrictions comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 550, at least about 600, at least about 650, at least about 700, at least about 750, at least about 800, at least about 850, at least about 900, at least about 950, at least about 1,000 or more individual constrictions.

73. The method of claim 71 or 72, wherein each of the plurality of constrictions is identical.

74. The method of claim 71 or 72, wherein one or more of the constrictions of the plurality of constrictions are different.

75. The method of claim 74, wherein one or more of the constrictions vary in length, depth, width, or a combination thereof.

76. The method of any one of claims 71 to 75, wherein each of the plurality of constrictions is associated with the same payload.

77. The method of any one of claims 71 to 75, wherein one or more of the plurality of constrictions are associated with different payloads.

78. The method of any one of claims 71 to 77, wherein the plurality of constrictions are contained within a single microfluidic chip.

79. The method of any one of claims 71 to 77, wherein the plurality of constrictions are contained within a plurality of microfluidic chips, wherein each of the plurality of microfluidic chips comprises a constriction.

80. The method of claim 79, wherein each of the plurality of microfluidic chips is identical.

81. The method of claim 79, wherein one or more of the plurality of microfluidic chips are different.

82. The method of any one of claims 71 to 81, wherein the time interval between passing the cell suspension through a first contraction and a second contraction of the plurality of contractions is less than about 1 μs, less than about 1 second, less than about 1 minute, less than about 30 minutes, less than about 1 hour, less than about 6 hours, less than about 12 hours, less than about 1 day, less than about 2 days, less than about 3 days, less than about 4 days, or less than about 5 days.

83. A method as claimed in claim 82, wherein the plurality of constrictions include a first constriction associated with a first payload and a second constriction associated with a payload, wherein passing the cell suspension through the first constriction allows the first payload to enter the HSC, and then passing the cell suspension through the second constriction allows the second payload to enter the HSC.

84. The method of any one of claims 1 to 83, further comprising administering to the subject the HSC that has been modified to contain the payload.

85. A hematopoietic stem cell (HSC) population produced using the method of any one of claims 1 to 5, 18, and 22 to 84.

86. A composition comprising the HSC population of claim 85, and a pharmaceutically acceptable carrier.

87. A composition comprising a population of modified hematopoietic stem cells (HSCs), wherein the modified HSCs comprise a payload that is capable of: (i) increasing the resistance of the modified HSCs to mobilization factors, (ii) increasing the resistance of the modified HSCs to inhibitors of anti-apoptotic factors, (iii) increasing the resistance of the modified HSCs to depletion factors, (iv) increasing the expression of homing factors on the modified HSCs, or (v) a combination thereof.

88. compositions as described in claim 87, wherein compared with the corresponding HSC that has not been modified to contain the payload, the resistance of the modified HSC to the mobilization factor is increased by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times.

89. compositions as claimed in claim 87 or 88, wherein compared with the corresponding HSC that has not been modified to contain the payload, the resistance of the modified HSC to the inhibitor of anti-apoptotic factor is increased by at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 40 times or at least about 50 times.

90. The composition of any one of claims 87 to 89, wherein the modified HSC has an increase in resistance to depletion factors by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that has not been modified to contain the payload.

91. The composition of any one of claims 87 to 90, wherein the expression of a homing receptor on the modified HSC is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold compared to a corresponding HSC that has not been modified to contain the payload.

92. A composition as described in any one of claims 87 to 91, wherein the payload is transiently expressed in the modified HSC.

93. compositions as described in any one in claim 87 to 92, wherein said effective load comprises homing receptor, cytokine, growth factor, cell adhesion molecule, proliferator, survival factor, their combination or their regulating and controlling agent.

94. The composition of claim 93, wherein the homing receptor comprises CXCR4, CXCR2, or both.

95. The composition of claim 94, wherein the CXCR4 comprises an amino acid sequence that is different from the corresponding wild-type amino acid sequence shown in SEQ ID NO:

1.

96. The composition of claim 95, wherein the amino acid sequence of the CXCR4 comprises one of the following mutations: R334X, A175F, H113A, D171N, D262N, I284A, H281A, Q200W, Q200A, or a combination thereof.

97. The composition of any one of claims 93 to 96, wherein the cytokine comprises stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), or both.

98. The composition of any one of claims 93 to 97, wherein the growth factor comprises thrombopoietin (TPO).

99. compositions as described in any one in claim 93 to 98, wherein said cell adhesion molecule comprises integrin, selectin or both.

100. The composition of claim 99, wherein the cell adhesion molecule comprises VLA-4, VLA-5, LFA-1, or a combination thereof.

101. The composition of any one of claims 93 to 100, wherein the proliferative agent comprises an activator of a signaling pathway involved in cell proliferation.

102. The composition of claim 101, wherein the signaling pathway comprises PI 3K-ATK, Ras-ERK, or both.

103. The composition of any one of claims 93 to 102, wherein the survival factor comprises Bcl-2, Bcl-xL, MCL-1, Ced-9, bfl-1, or a combination thereof.

104. The composition of claim 103, wherein the Bcl-2 comprises an amino acid sequence that is different from the corresponding wild-type amino acid sequence shown in SEQ ID NO:

9.

105. The composition of claim 104, wherein the amino acid sequence of the Bcl-2 comprises a G101V mutation, a D103Y mutation, or both.

106. A composition as described in any one of claims 93 to 105, wherein the regulating agent is capable of increasing expression and / or the activity of the homing receptor, the cytokine, the growth factor, the cell adhesion molecule, the proliferator, the survival factor, or a combination thereof.

107. The composition of claim 106, wherein the modulating agent comprises a prostaglandin (e.g., prostaglandin E2 (PGE2)).

108. The composition of any one of claims 93 to 107, wherein the regulating agent is capable of reducing or preventing (e.g., knocking down) the activity of an inhibitor of the homing receptor, the cytokine, the growth factor, the cell adhesion molecule, the proliferator, the survival factor, or a combination thereof.

109. The composition of claim 108, wherein the inhibitor comprises GPRASP1 / 2, CD26, or both.

110. The composition of any one of claims 87 to 109, wherein the mobilization factor comprises plerixafor, AMD3465, GROβ, G-CSF, an anti-CD117 antibody, or a combination thereof.

111. The composition of any one of claims 87 to 110, wherein the apoptotic factor comprises a Bcl-2 inhibitor (eg, venetoclax), an MCL-1 inhibitor (eg, S63845 or S64315), a BCL-XL inhibitor, or a combination thereof.

112. The composition of any one of claims 87 to 111, wherein the payload comprises a nucleic acid.

113. The composition of claim 112, wherein the nucleic acid comprises DNA, RNA, or both.

114. The composition of claim 113, wherein the RNA comprises mRNA, siRNA, miRNA, lncRNA, tRNA, shRNA, self-amplifying mRNA (saRNA), PNA, locked nucleic acid (LNA), or a combination thereof.

115. A kit comprising the HSC population of claim 85 and instructions for use.

116. A composition as described in claim 86 or 87, for use in a method of treating a disease or condition in a subject in need thereof, wherein the method comprises administering the composition to the subject.

117. The composition for use of claim 116, wherein the disease or disorder comprises a blood disorder.

118. The composition for use of claim 117, wherein the blood disorder comprises sickle cell disease (SCD), thalassemia syndrome, severe aplastic anemia, Fanconi anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, congenital amegakaryocytic thrombocytopenia, or a combination thereof.

119. The composition for use of claim 116, wherein the disease or disorder comprises an immune disorder.

120. The composition for use of claim 119, wherein the immune disorder comprises severe combined immunodeficiency, Wistar-Oberleutreich syndrome, or both.

121. The composition for use of claim 116, wherein the disease or disorder comprises a metabolic disorder.

122. The composition for use of claim 121, wherein the metabolic disorder comprises Krabbe disease (GLD), Hurler syndrome, adrenoleukodystrophy, metachromatic leukodystrophy, Fabry disease, Gaucher disease, cystinosis, Hunter syndrome, Pompe disease, or a combination thereof.

123. The composition for use of any one of claims 116 to 122, wherein the subject has not received a myeloablative conditioning regimen prior to the administration of the composition.

124. The composition for use of claim 123, wherein the myeloablative conditioning regimen comprises irradiation, chemotherapy, small molecules, antibodies, or a combination thereof.

125. The composition for use of any one of claims 116 to 124, further comprising administering another dose to the subject.

126. The composition for use of claim 125, wherein the additional agent comprises a mobilization factor, an apoptotic factor, or both.